Vaccines and related methods

WO2024151583A3PCT designated stage expired Publication Date: 2024-11-07FLAGSHIP PIONEERING INNOVATIONS VII LLC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/010810
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-01-09
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current SARS-CoV-2 vaccines and antibody therapies face challenges due to the potential for SARS-CoV-2 variants to evade vaccine-induced immunity and antibody therapies, as most target the receptor binding domain (RBD) of the spike protein, which is prone to variations.

Method used

Development of novel SARS-CoV-2 spike proteins and nucleic acid molecules, such as mRNAs, with specific sequence variations that counter resistance, used in pharmaceutical compositions and vaccines to induce immune responses against multiple variants.

Benefits of technology

These novel immunogens and vaccines aim to provide variant-proof or variant-resistant immunity, enhancing the effectiveness against evolving SARS-CoV-2 strains by targeting specific sequence variations in the spike protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024010810_07112024_PF_FP_ABST
    Figure US2024010810_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and / or amelioration of a SARS-CoV-2 infection; vaccination against SARS-CoV-2.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Attorney Docket No.62801.16WO01 VACCINES AND RELATED METHODS RELATED APPLICATIONS This application claims priority to U.S. Serial No.: 63 / 479,073, filed January 9, 2023, and U.S. Serial No.: 63 / 504,508, filed May 26, 2023, the entire contents of each of which is incorporated herein by reference. 1. FIELD This disclosure relates to SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (and immunogenic fragments and / or immunogenic variants thereof)), that comprise at least one set of amino acid substitutions (described herein) and nucleic acid molecules encoding the same. The disclosure further relates to compositions comprising of the same (e.g., vaccine compositions, pharmaceutical compositions) and methods of making and utilizing the same. 2. BACKGROUND Coronaviruses are a family of enveloped, positive-sense, single stranded RNA viruses that infect a wide variety of mammalian and avian species. The viral genome is packaged into a capsid that is comprised of the viral nucleocapsid protein and surrounded by a lipid envelope. Embedded in the lipid envelope are several proteins, including, the membrane protein, the envelope small membrane protein, hemagglutinin-esterase, and the spike protein. Human coronaviruses typically cause respiratory illnesses, and include, e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), and Middle East respiratory syndrome (MERS-CoV). SARS-Cov-2 emerged in humans in 2019, spread rapidly, and led to an ongoing global pandemic. SARS-CoV-2 is the cause of the coronavirus disease 2019 (COVID-19). COVID-19 has caused a continuing public health crisis, with millions of deaths and severe illness attributed to COVID-19 worldwide. Protection against COVID-19 is mediated in large part by an immune response directed against the SARS-CoV-2 spike protein, a main target of SARS-CoV-2 vaccines. The spike protein mediates binding and entry into host cells, through binding of the receptor binding domain (RBD) to the host cell receptor angiotensin-converting enzyme 2 (ACE2). Attorney Docket No.62801.16WO01 3. SUMMARY Provided herein are, inter alia, SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (and immunogenic fragments and / or immunogenic variants thereof)), nucleic acids encoding the same, compositions (e.g., vaccine compositions, pharmaceutical compositions) comprising the SARS-CoV-2 spike proteins (e.g., SARS-CoV- 2 spike protein immunogens (and immunogenic fragments and / or immunogenic variants thereof)) or nucleic acids encoding the same, methods of manufacturing, and methods of use including, e.g., methods of preventing, reducing, or treating a SARS-CoV-2 infection, methods of vaccination against a SARS-CoV-2 infection, etc. In one aspect, provided herein are nucleic acid molecules comprising at least one coding region encoding a SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), comprises at least one set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) comprises a SARS-CoV-2 spike protein receptor binding domain (RBD). In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) consists of a SARS-CoV-2 spike protein receptor binding domain (RBD). In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) comprises a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) consists of a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a full-length SARS-CoV-2 spike protein. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the Attorney Docket No.62801.16WO01 SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consist of a full-length SARS-CoV-2 spike protein. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10- 80, 10-90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10-1100, 10-1200, or 10-1300 amino acids. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 1-5). In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 1-5). In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or Attorney Docket No.62801.16WO01 immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 1-5). In some embodiments, the encoded SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-2, that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, the encoded SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non- naturally occurring glycosylation site. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring Attorney Docket No.62801.16WO01 glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1- 10. In some embodiments, the non-naturally occurring glycosylation site is an N-glycosylation site. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 3. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-28. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-16. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-22. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 23-28. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic Attorney Docket No.62801.16WO01 variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10). In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10). In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10). In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, Attorney Docket No.62801.16WO01 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 5. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2 and the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or Attorney Docket No.62801.16WO01 immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 4. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than Attorney Docket No.62801.16WO01 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises an inactive furin cleavage site. In some embodiments, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation in the furin cleavage site that inactivates the furin cleavage site. In some embodiments, the encoded SARS-CoV-2 spike protein is an immunogen (or an immunogenic fragment and / or immunogenic variant thereof). In some embodiments, the nucleic acid molecule is an RNA molecule, a DNA molecule, or a DNA / RNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule. In some embodiments, the RNA molecule is a translatable RNA molecule. In some embodiments, the RNA molecule is a messenger RNA (mRNA) molecule. In some embodiments, the RNA molecule is a circular RNA molecule. In some embodiments, the nucleotide sequence of the nucleic acid molecule is codon optimized. In some embodiments, the nucleic acid molecule comprises at least one modified nucleotide. In some embodiments, the nucleic acid molecule comprises N1-methyl- pseudouridine, cytosine, adenine, and guanine. In some embodiments, the nucleic acid molecule comprises a heterologous 5’- untranslated region (UTR), 3’-UTR, or both a 5’-UTR and 3’-UTR. In some embodiments, the nucleic acid molecule comprises a poly(A) sequence. In some embodiments, the nucleic acid molecule comprises a 5’cap structure. In some embodiments, the nucleic acid molecule further encodes a heterologous protein. In some embodiments, the nucleic acid molecule encodes a signal peptide. In some embodiments, the nucleic acid molecule encodes a homologous or heterologous signal peptide. In some embodiments, the nucleic acid molecule does not encode a signal peptide. In one aspect, provided herein are vectors comprising a nucleic acid molecule described herein. In some embodiments, the vector is a non-viral vector (e.g., a plasmid) or a viral vector. Attorney Docket No.62801.16WO01 In one aspect, provided herein are conjugates comprising a nucleic acid molecule described herein operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous moiety (e.g., a heterologous protein). In one aspect, provided herein are compositions comprising at least one nucleic acid molecule described herein, a vector described herein, or a conjugate described herein. In some embodiments, the composition comprises a plurality of nucleic acid molecules described herein, wherein the amino acid sequence of each of the SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) encoded by each nucleic acid molecule of the plurality is different. In some embodiments, the plurality comprises at least two nucleic acid molecules described herein, wherein the amino acid sequence of each of the SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) encoded by of each of the at least 2 nucleic acid molecules comprises a different set of amino acid substitutions set forth in Table 2 or Table 4 or a different combination of sets of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the composition further comprises a nucleic acid molecule encoding a SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the nucleic acid molecule(s) or the one or more vectors are formulated in one or more carrier. In some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient or a vaccine composition. In some embodiments, the composition further comprising an adjuvant. In some embodiments, the nucleic acid molecule(s) are comprised in one or more vectors. In some embodiments, the composition further comprises a carrier. In some embodiments, the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm. In one aspect, provided herein are compositions comprising (a) at least one nucleic acid molecule comprising at least one set of amino acid substitutions set forth in Table 2; (b) at least one nucleic acid molecule comprising at least one set of amino acid substitutions set forth in Table 4; and / or (c) at least one nucleic acid molecule comprising at least one set of Attorney Docket No.62801.16WO01 amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, the composition further comprises a nucleic acid molecule encoding a SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the nucleic acid molecule(s) or the one or more vectors are formulated in one or more carrier. In some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient or a vaccine composition. In some embodiments, the composition further comprising an adjuvant. In some embodiments, the nucleic acid molecule(s) are comprised in one or more vectors. In some embodiments, the composition further comprises a carrier. In some embodiments, the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm. In one aspect, provided herein are SARS-CoV-2 spike protein (e.g., a SARS-CoV- 2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), comprises at least one set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a SARS-CoV-2 spike protein receptor binding domain (RBD). In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) consists of a SARS-CoV-2 spike protein receptor binding domain (RBD). In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) consists of a fragment of a full- length SARS-CoV-2 spike protein that retains the ability to bind ACE2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a full-length SARS-CoV-2 spike protein. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) consists of a full-length SARS-CoV-2 spike protein. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10- 60, 10-70, 10-80, 10-90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10- 900, 10-1000, 10-1100, 10-1200, or 10-1300 amino acids. In some embodiments, other than the at least one set of amino acid substitutions, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-5. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. Attorney Docket No.62801.16WO01 In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic Attorney Docket No.62801.16WO01 fragment and / or immunogenic variant thereof)) comprises the addition of one or more non- naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the non-naturally occurring glycosylation site is an N-glycosylation site. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 3. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-28. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-16. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-22. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 23-28. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4. In some embodiments, other than the at least one set of amino acid substitutions the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein Attorney Docket No.62801.16WO01 immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 6-10. In some embodiments, other than the at least one set of amino acid substitutions the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 5. Attorney Docket No.62801.16WO01 In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, other than the at least one set of amino acid substitutions, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2 and the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least Attorney Docket No.62801.16WO01 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein Attorney Docket No.62801.16WO01 (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises an inactive furin cleavage site. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation in the furin cleavage site that inactivates the furin cleavage site. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) further comprises a heterologous protein. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a signal peptide. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a homologous or heterologous signal peptide. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) does not comprise a signal peptide. In some embodiments, the SARS-CoV-2 spike protein is an immunogen (or an immunogenic fragment and / or immunogenic variant thereof). In one aspect, provided herein are fusion proteins comprising a SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous protein. In one aspect, provided herein are conjugates comprising a SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous moiety. Attorney Docket No.62801.16WO01 In one aspect, provided herein are compositions comprising at least one SARS- CoV-2 spike protein (e.g., at least one of the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein, a fusion protein described herein, a conjugate described herein, or a nucleic acid molecule described herein. In some embodiments, the composition comprises a plurality of SARS-CoV-2 spike proteins (e.g., a plurality of SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) described herein, wherein the amino acid sequence of each of the plurality of SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 2 or Table 4 or a different combination of sets of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the composition further comprises a SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient. In some embodiments, the composition further comprises an adjuvant. In some embodiments, the SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) are formulated in one or more carrier. In some embodiments, the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm. In one aspect, provided herein are compositions comprising (a) at least one SARS- CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein that comprises at least one set of amino acid substitutions set forth in Table 2; (b) at least one SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein that comprises at least one set of amino acid substitutions set forth in Table 4; and / or (c) at least one SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic Attorney Docket No.62801.16WO01 variant thereof)) described herein that comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, the composition further comprises a SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient. In some embodiments, the composition further comprises an adjuvant. In some embodiments, the SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) are formulated in one or more carrier. In some embodiments, the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm. In one aspect, provided herein are nucleic acid molecules encoding a SARS-CoV- 2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein. In one aspect, provided herein are SARS-CoV-2 spike proteins (e.g., a SARS-CoV- 2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) encoded by a nucleic acid molecule described herein. In one aspect, provided herein are carriers comprising a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a vaccine composition described herein, or a pharmaceutical composition described herein. In some embodiments, the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm. In one aspect, provided herein are vaccine compositions comprising a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, or a pharmaceutical composition described herein. In some embodiments, the vaccine composition is a prime vaccine composition. In some embodiments, the vaccine composition is a boost vaccine composition. In some embodiments, the vaccine composition is a prime vaccine composition and a boost vaccine composition. In some embodiments, the vaccine composition can be utilized as a prime vaccine composition and / or a booster vaccine composition in a homologous or heterologous prime boost vaccine regimen. In some embodiments, the vaccine composition further comprises an adjuvant. In one aspect, provided herein are vaccine compositions comprising a messenger ribonucleic acid (mRNA) encoding a SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) that comprises at least one amino acid substitution set forth in Table 2 or Table 4, formulated in a lipid nanoparticle, the vaccine composition having the following characteristics: (a) the LNPs comprise a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid, (b) the LNPs have a mean particle size of between 80 nm and 160 nm, and (c) the mRNA comprises: (i) a 5'-cap structure; (ii) a 5'-UTR; (iii) N1-methyl-pseudouridine, cytosine, adenine, and guanine; (iv) a 3'-UTR; and (v) a poly-A region. In some embodiments, the vaccine composition further comprises an adjuvant. In one aspect, provided herein are pharmaceutical compositions comprising a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, or a vaccine composition described herein, and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an adjuvant. In one aspect, provided herein are pharmaceutical compositions comprising a messenger ribonucleic acid (mRNA) encoding a SARS-CoV-2 spike protein (e.g., a SARS- CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) that comprises at least one amino acid substitution set forth in Table 2 or Table 4, formulated in a lipid nanoparticle, the pharmaceutical composition having the following characteristics: (a) the LNPs comprise a cationic lipid, a neutral lipid, a cholesterol, and a PEG Attorney Docket No.62801.16WO01 lipid, (b) the LNPs have a mean particle size of between 80 nm and 160 nm, and (c) the mRNA comprises: (i) a 5'-cap structure; (ii) a 5'-UTR; (iii) N1-methyl-pseudouridine, cytosine, adenine, and guanine; (iv) a 3'-UTR; and (v) a poly-A region. In some embodiments, the pharmaceutical composition further comprises an adjuvant. In one aspect, provided herein are host cells comprising a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein. In one aspect, provided herein are kits comprising a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein. In some embodiments, the kit comprises instructions for use of the nucleic acid molecule, vector, protein (or immunogenic fragment or immunogenic variant thereof), conjugate, fusion protein, carrier, composition, vaccine composition, or pharmaceutical composition. In one aspect, provided herein are methods of delivering a nucleic acid molecule, vector, protein (or immunogenic fragment or immunogenic variant thereof), conjugate, fusion protein, host cell, carrier, composition, vaccine composition, or pharmaceutical composition to a subject in need thereof, the method comprising administering to the subject a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby deliver the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject. Attorney Docket No.62801.16WO01 In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. In one aspect, provided herein are methods of inducing or enhancing an immune response in a subject in need thereof, the method comprising administering to a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby induce or enhance an immune response the subject. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion Attorney Docket No.62801.16WO01 protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. In one aspect, provided herein are methods of preventing, ameliorating, or treating a SARS-CoV-2 infection in a subject in need thereof, the method comprising administering to the subject a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby prevent, ameliorate, or treat the SARS-CoV-2 infection the subject. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. In one aspect, provided herein are methods of vaccinating a subject against SARS- CoV-2, the method comprising administering to the subject a nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby vaccinate the subject against SARS-CoV-2. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment Attorney Docket No.62801.16WO01 and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. In one aspect, provided herein are methods of vaccinating a subject against SARS- CoV-2, the method comprising administering to the subject (a) an mRNA molecule (e.g., an mRNA molecule described herein) encoding the SARS-CoV-2 spike protein (e.g., a SARS- CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186 (or a conjugate or fusion protein thereof), (b) a vector comprising the mRNA molecule, (c) a carrier comprising the mRNA molecule or the vector, (d) a vaccine composition comprising the mRNA molecule, the vector, or the carrier, or (e) a pharmaceutical composition comprising the mRNA molecule, the vector, the carrier, or the vaccine composition, to thereby vaccinate the subject against SARS- CoV-2, to thereby vaccinate the subject against SARS-CoV-2. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion Attorney Docket No.62801.16WO01 protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. In one aspect, provided herein are methods of vaccinating a subject against SARS- CoV-2, the method comprising administering to the subject a vaccine composition described herein or a pharmaceutical composition described herein, to thereby vaccinate the subject against SARS-CoV-2. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use in the manufacture of a medicament for the inducement and / or enhancement of an immune response in a subject in need thereof. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), Attorney Docket No.62801.16WO01 the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use in the manufacture of a medicament for the prevention, amelioration, and / or treatment of a SARS-CoV-2 infection in a subject in need thereof. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition Attorney Docket No.62801.16WO01 described herein for use in the manufacture of a medicament for the vaccination a subject against SARS-CoV-2. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use a method of inducing or enhancing an immune response in a subject in need thereof, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or Attorney Docket No.62801.16WO01 heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use in a method of preventing, ameliorating, and / or treating a SARS-CoV- 2 infection in a subject in need thereof, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. A nucleic acid molecule described herein, a protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) described herein, a vector described herein, a conjugate described herein, a fusion protein described herein, a host cell described herein, a composition described herein, a carrier described herein, a vaccine composition described herein, or a pharmaceutical composition Attorney Docket No.62801.16WO01 described herein for use in a method of vaccinating a subject against SARS-CoV-2, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice. In some embodiments, the subject is a human. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen. In some embodiments, the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen. 4. BRIEF DESCRIPTION OF THE FIGURES FIGS. 1A-1C depict a sequence alignment of the amino acid sequence of a reference SARS-CoV-2 spike protein Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1) and a variant thereof (SEQ ID NO: 6). 5. DETAILED DESCRIPTION SARS-CoV-2 continues to evolve into new variants comprising a variety of amino acid variations, e.g., substitutions, deletions, and insertions. Many of the variations are found in the RBD of the spike protein, which is vital for SARS-CoV-2 entry into the cell. As most of the SARS-CoV-2 vaccines and current antibody therapies target the RBD of the spike protein, this creates the potential for the evolution of SARS-CoV-2 variants that evade vaccine-induced, infection-induced immunity, or current antibody therapies. The inventors have identified sequence variations in the SARS-CoV-2 spike protein (e.g., in the RBD) that e.g., counter SARS-CoV-2 resistance to vaccine induced immunity and / or are potential SARS-CoV-2 variants. Accordingly, novel SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein Attorney Docket No.62801.16WO01 immunogens (and immunogenic fragments and / or immunogenic variants thereof)) (or nucleic acid molecules, e.g., mRNAs, encoding such SARS-CoV-2 spike proteins) comprising at least one such sequence variation are good candidates for variant-proof or variant-resistant vaccines against COVID-19. A such, the current disclosure provides, inter alia, novel immunogens for use in pharmaceutical compositions and vaccines to induce a desired immune response against one or more variants of SARS-CoV-2. TABLE OF CONTENTS 5.1 Definitions 5.2 SARS-CoV-2 Spike Proteins (e.g., Immunogens) 5.2.1 Exemplary Additional Features of SARS-CoV-2 Spike Proteins (e.g., Immunogens) 5.2.1.1 Full-Length Spike Proteins and Receptor Binding Fragments 5.2.1.2 Stabilization 5.2.1.3 Multimerization (e.g., Trimerization) Domains 5.2.1.4 Engineered Glycosylation Sites 5.2.1.5 Hyperglycosylation 5.2.1.6 Additional Variations 5.2.1.7 Variations from Different Strains of SARS-CoV-2 5.3 Nucleic Acid Molecules 5.3.1 DNA Molecules 5.3.2 RNA Molecules 5.4 Fusions & Conjugates 5.5 Vaccine Compositions 5.5.1 Peptide and Protein-Based Vaccines 5.5.2 Nucleic Acid-Based Vaccines 5.6 Vectors 5.7 Carriers Attorney Docket No.62801.16WO01 5.7.1 Lipid Based Carriers / Lipid Nanoformulations 5.7.1.1 Cationic Lipids (Positively Charged) and Ionizable Lipids 5.7.1.2 Non-Cationic Lipids (e.g., Phospholipids) 5.7.1.3 Structural Lipids 5.7.1.4 Polymers and Polyethylene Glycol (PEG) - Lipids 5.7.1.5 Percentages of Lipid Nanoformulation Components 5.8 Pharmaceutical Compositions 5.9 Adjuvants 5.10 Host Cells 5.11 Methods of Making Polypeptides & Proteins 5.12 Methods of Making Nucleic Acid Molecules 5.13 Methods of Use 5.13.1 Methods of Delivery 5.13.2 Methods of Inducing or Enhancing an Immune Response 5.13.3 Methods of Preventing, Ameliorating, and / or Treating Infection 5.13.4 Methods of Vaccination against SARS-CoV-2 5.13.5 Methods of Vaccinating a Subject against SARS-CoV-2 5.13.6 Methods of Vaccinating a Subject Utilizing a SARS-CoV-2 mRNA Vaccine 5.14 Kits 5.1 Definitions The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. Attorney Docket No.62801.16WO01 In this application, the use of the singular includes the plural unless specifically stated otherwise. For example, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Furthermore, use of the term “including” as well as other forms, such as “include,” “includes,” and “included,” is not limiting. It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of” and “consisting essentially of” are also provided. The term “and / or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. The terms “about” refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” should be assumed to be within an acceptable error range for that particular value or composition. Where proteins are described herein, it is understood that polynucleotides (e.g., RNA (e.g., mRNA) or DNA nucleic acid molecules) encoding the protein are also provided herein. Where proteins, polypeptides, nucleic acid molecules, vectors, carriers, etc. are described herein, it is understood that isolated forms of the proteins, nucleic acid molecules, vectors, carriers, etc. are also provided herein. Where proteins, polypeptides, nucleic acid molecules, etc. are described herein, it is understood that recombinant forms of the proteins, nucleic acid molecules, etc. are also provided herein. Attorney Docket No.62801.16WO01 Where polypeptides or sets of polypeptides are described herein, it is understood that proteins comprising the polypeptides or sets of polypeptides folded into their three- dimensional structure (i.e., tertiary or quaternary structure) are also provided herein and vice versa. As used herein, the term “adjuvant” refers to a substance that causes stimulation of the immune system of a subject when administered to the subject. As used herein, the term “administering” refers to the physical introduction of an agent, e.g., a vaccine or therapeutic agent (or a precursor of the therapeutic agent that is metabolized or altered (e.g., translation of a nucleic acid molecule) within the body of the subject to produce the therapeutic agent in vivo) to a subject, using any of the various methods and delivery systems known to those skilled in the art. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods. As used herein, the term “agent” is used generically to describe any macro or micro molecule. Exemplary moieties include, but are not limited to polypeptides, proteins, peptides, nucleic acid molecules (e.g., DNA, RNA), small molecules, carbohydrates, lipids, synthetic polymers (e.g., polymers of PEG). As used herein, the term “circular RNA” refers to a translatable RNA molecule that forms a circular structure through covalent or non-covalent bonds. As used herein, the term “derived from,” with reference to a polynucleotide refers to a polynucleotide that has at least 70% sequence identity to a reference polynucleotide (e.g., a naturally occurring polynucleotide) or a fragment thereof. The term “derived from,” with reference to a polypeptide or protein refers to a polypeptide or protein that comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence of a reference polypeptide or protein (e.g., a naturally occurring polypeptide or protein). The term “derived from” as used herein does not denote any specific process or method for obtaining the polynucleotide, polypeptide, or protein. For example, the polynucleotide, polypeptide, or protein can be recombinant produced or chemically synthesized. As used herein, the term “disease” refers to any abnormal condition that impairs physiological function. The term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition, or syndrome in which physiological function is impaired, irrespective of the nature of the etiology. The term disease includes infection (e.g., a viral (e.g., a SARS-Cov-2 infection), bacterial, fungal, protozoal infection). The terms “DNA” and “polydeoxyribonucleotide” are used interchangeably herein and refer to macromolecules that include multiple deoxyribonucleotides that are polymerized Attorney Docket No.62801.16WO01 via phosphodiester bonds. Deoxyribonucleotides are nucleotides in which the sugar is deoxyribose. As used herein, the term “full-length” with reference to a SARS-CoV-2 spike protein refers to a SARS-CoV-2 spike protein, wherein the amino acid sequence of the SARS- CoV-2 spike protein comprises substantially the same number of amino acids as a reference SARS-CoV-2 spike protein. As used herein, the term “fuse” and grammatical equivalents thereof refer to the operable connection of at least a first polypeptide or protein to a second polypeptide or protein, wherein the first and second polypeptides or proteins are not naturally found operably connected together. For example, the first and second polypeptides or proteins are derived from different proteins. The term fuse encompasses both a direct connection of the at least two polypeptides or proteins through a peptide bond, and the indirect connection through a linker (e.g., a peptide linker). As used herein, the term “heterologous”, when used to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described. For example, a polypeptide comprising a “heterologous moiety” means a polypeptide that is joined to a moiety (e.g., small molecule, polypeptide, polynucleotide, carbohydrate, lipid, synthetic polymer (e.g., polymers of PEG), etc.) that is not joined to the polypeptide in nature. As used herein, the term “fusion protein” and grammatical equivalents thereof refers to a protein that comprises at least one polypeptide operably connected to another polypeptide, wherein the first and second polypeptides are different and not naturally found operably connected together. For example, the first and second polypeptides of the fusion protein are each derived from different proteins. The at least two polypeptides of the fusion protein can be directly operably connected through a peptide bond; or can be indirectly operably connected through a linker (e.g., a peptide linker). Therefore, for example, the term fusion polypeptide encompasses embodiments, wherein Polypeptide A is directly operably connected to Polypeptide B through a peptide bond (Polypeptide A – Polypeptide B), and embodiments, wherein Polypeptide A is operably connected to Polypeptide B through a peptide linker (Polypeptide A – peptide linker – Polypeptide B). As used herein, the term “glycosylation site” refers to the amino acid residue of a protein or peptide which is the attachment point for a glycan. For example, in N-linked glycosylation, the glycosylation site will be the asparagine residue to which the glycan is attached. For further example, in O-linked glycosylation, the glycosylation site will be the Attorney Docket No.62801.16WO01 serine or threonine residue to which the glycan is attached. The term “non-naturally occurring glycosylation site” within a protein or peptide refers to a glycosylation site that is not found in a specific protein or peptide in nature. The non-naturally occurring glycosylation site can be generated by creating a non-naturally occurring glycosylation motif, which does not necessarily require varying the amino acid of the glycosylation site. For example, a non- naturally occurring glycosylation site would include a glycosylation site generated from the variation of a N-A-P amino acid sequence of a protein to a N-A-T amino acid sequence (creating an N-linked glycosylation motif) even though the amino acid that mediates attachment of the glycan (N) was not varied. As used herein, the term “glycosylation motif” refers to the amino acid or sequence of amino acids that comprises the glycosylation site and facilities glycosylation. For example, in N-linked glycosylation, the canonical glycosylation motifs are NXT and NXS, wherein X is any amino acid except for proline and the asparagine (N) residue is the glycosylation site. For further example, in O-linked glycosylation, the glycosylation motif is a S or T residue that also serves as the glycosylation site. As used herein, the term “half-life extension protein or “half-life extension polypeptide” refers to a polypeptide or protein that when operably connected to another moiety (e.g., a subject moiety) (e.g., a protein), increases the half-life of the subject moiety (e.g., the subject protein) in vivo when administered to a subject (e.g., a human subject). The pharmacokinetic properties of the protein can be evaluated utilizing in vivo models known in the art. As used herein, the term “heterologous”, when used to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described. For example, a polypeptide comprising a “heterologous moiety” means a polypeptide that is joined to a moiety (e.g., small molecule, polypeptide, nucleic acid molecule, carbohydrate, lipid, synthetic polymer (e.g., polymers of PEG), etc.) that is not joined to the polypeptide in nature. As used, herein the term “heterologous signal peptide” refers to a signal peptide that is not operably connected to a subject polypeptide or protein in nature. For example, in reference to a polypeptide comprising a signal peptide from human IL-2 operably connected to human IL-12, the human IL-2 signal peptide would constitute a heterologous signal peptide. As used herein, the term “heterologous prime boost” refers to a prime boost vaccine regimen wherein the prime vaccine composition and the boost (or booster) vaccine composition are different (e.g., the immunogen is different, the form of the immunogen is different (e.g., a Attorney Docket No.62801.16WO01 nucleic acid (e.g., mRNA) molecule-based vaccine versus a protein-based vaccine), the immunogen is expressed from a different vector (e.g., plasmid, viral vector), the method of delivering the immunogen to the subject is different, etc.). As used herein, the term “homologous signal peptide” refers to a signal peptide that is operably connected to a subject polypeptide or protein in nature. For example, in reference to a polypeptide comprising a signal peptide from human IL-2 operably connected to human IL-2, the human IL-2 signal peptide would constitute a homologous signal peptide. As used herein, the term “homologous prime boost” refers to a prime boost vaccine regimen wherein the prime vaccine composition and the boost (or booster) vaccine composition are the same. As used herein, the term “immunogen” refers to a substance that is capable of inducing an immune response (e.g., an adaptive immune response) in a subject (e.g., a human subject). As used herein, the term “immunogenic fragment” refers to a fragment of a reference polypeptide or protein that retains an immunogen. As used herein, the term “immunogenic variant” refers to a variant of a reference polypeptide or protein that retains an immunogen. In some embodiments, the polypeptide or protein comprises at least one but no more than 25%, (e.g., no more than 20%, no more than 15%, no more than 12%, no more than 10%, no more than 8%) amino acid variation (e.g., substitutions, deletions, additions) compared to the amino acid sequence of a reference polypeptide or protein. As used herein, the term “in combination with” means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent and the agents may be co-formulated. In other embodiments, the two or more agents are not co- formulated and are administered in a sequential manner as part of a prescribed regimen (e.g., a prime-boost vaccine regimen). In some embodiments, administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disease is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous administration of each agent can be effected by any appropriate route including, Attorney Docket No.62801.16WO01 but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The agents can be administered by the same route or by different routes. As used herein, the term “isolated” with reference to an agent (e.g., a polypeptide, protein, or nucleic acid molecule) refers to the agent (e.g., the polypeptide, protein, or nucleic acid molecule) that is substantially free of other cellular components with which it is associated in the natural state. As used herein, the term “modification” in reference to a nucleic acid sequence refers to a nucleic acid molecule that comprises at least one nucleotide comprising a chemical modification, e.g., a modified sugar moiety, a modified nucleobase, and / or a modified internucleotide linkage, or any combination thereof. Exemplary nucleotide modifications are provided herein, see, e.g., § 5.3 (e.g., § 5.3.2). In certain embodiments of the instant disclosure, inclusion of a deoxynucleotide - which is acknowledged as a naturally occurring form of nucleotide - if present within an RNA molecule (e.g., an mRNA molecule) is considered to constitute a modified nucleotide. The terms “nucleic acid molecule” and “polynucleotide” are used interchangeably herein and refer to a polymer of DNA or RNA. The nucleic acid molecule can be single- stranded or double-stranded; contain natural, non-natural, or altered nucleotides; and contain a natural, non-natural, or altered internucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule. Nucleic acid molecules include, but are not limited to, all nucleic acid molecules which are obtained by any means available in the art, including, without limitation, recombinant means, e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and by synthetic means. The skilled artisan will appreciate that, except where otherwise noted, nucleic acid sequences set forth in the instant application will recite thymidine (T) in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the thymidines (Ts) would be substituted for uracils (Us). Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each thymidine (T) of the DNA sequence is substituted with uracil (U). As used herein, the term “operably connected” refers to the linkage of two moieties in a functional relationship. For example, a polypeptide is operably connected to another polypeptide when they are linked (either directly or indirectly via a peptide linker) in frame Attorney Docket No.62801.16WO01 such that both polypeptides are functional (e.g., a fusion protein described herein). Or for example, a transcription regulatory polynucleotide e.g., a promoter, enhancer, or other expression control element is operably connected to a polynucleotide that encodes a protein if it affects the transcription of the polynucleotide that encodes the protein. The term “operably connected” can also refer to the conjugation of a moiety to e.g., a polynucleotide or polypeptide (e.g., the conjugation of a PEG polymer to a protein). The determination of “percent identity” between two sequences (e.g., peptide or protein (amino acid sequences) or nucleic acid sequences)) can be accomplished using a mathematical algorithm. A specific, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin S & Altschul SF (1990) PNAS 87: 2264-2268, modified as in Karlin S & Altschul SF (1993) PNAS 90: 5873-5877, each of which is herein incorporated by reference in its entirety. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul SF et al., (1990) J Mol Biol 215: 403, which is herein incorporated by reference in its entirety. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecule described herein. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score 50, wordlength=3 to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul SF et al., (1997) Nuc Acids Res 25: 3389-3402, which is herein incorporated by reference in its entirety. Alternatively, PSI BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., National Center for Biotechnology Information (NCBI) on the worldwide web, ncbi.nlm.nih.gov). Another specific, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17, which is herein incorporated by reference in its entirety. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted. Attorney Docket No.62801.16WO01 As used herein the term “pharmaceutical composition” means a composition that is suitable for administration to an animal, e.g., a human subject, and comprises a therapeutic agent and a pharmaceutically acceptable carrier or diluent. A “pharmaceutically acceptable carrier or diluent” means a substance for use in contact with the tissues of human beings and / or non-human animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable therapeutic benefit / risk ratio. As used herein, the term “plurality” means 2 or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 9 or more, or 10 or more). As used herein, the term “poly(A) sequence,” refers to a sequence of adenosine nucleotides, typically located at the 3’-end of a linear RNA (or in a circular RNA), of up to about 1000 adenosine nucleotides. In some embodiments, the poly(A) sequence is essentially homopolymeric, e.g., a poly(A) sequence of e.g., 100 adenosine nucleotides has essentially the length of 100 nucleotides. In other embodiments, the poly(A) sequence may be interrupted by at least one nucleotide different from an adenosine nucleotide, e.g., a poly(A) sequence of e.g., 100 adenosine nucleotides may have a length of more than 100 nucleotides (comprising 100 adenosine nucleotides and in addition said at least one nucleotide - or a stretch of nucleotides - different from an adenosine nucleotide). It has to be understood that “poly(A) sequence” as defined herein typically relates to RNA - however in the context of the invention, the term likewise relates to corresponding sequences in a DNA molecule (e.g. a “poly(T) sequence”). As used herein, the term “prime boost” refers to a vaccine regimen comprising at least an initial vaccine dose and one or more subsequent vaccine doses. The initial vaccine dose comprises the prime vaccine composition and the one or more subsequent vaccine doses are referred to as boost (or booster) vaccine compositions. Prime boost vaccine regimens can comprise more than one booster (e.g., 2, 3, 4, 5, 6, or more, etc.). A “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs of a disease or exhibits only early signs for the purpose of decreasing the risk of developing pathology. As used herein, the term “polypeptide” refers to a polymer of at least 2 (e.g., at least 5) amino acids linked by a peptide bond. The term “polypeptide” does not denote a specific length of the polymer chain of amino acids. It is common in the art to refer to shorter polymers of amino acids (e.g., approximately 2-50 amino acids) as peptides; and to refer to longer polymers of amino acids (e.g., approximately over 50 amino acids) as polypeptides. However, the terms “peptide” and “polypeptide” are used interchangeably herein. Attorney Docket No.62801.16WO01 As used herein, the term “protein” refers to one or more polypeptides folded into its three-dimensional structure. Where polypeptides are contemplated herein, it should be understood that proteins comprising the polypeptides (i.e., the polypeptides folded unto their three-dimensional structure) are also provided herein. As used herein, the term “receptor binding domain” or “RBD” in reference to the SARS-CoV-2 spike protein refers to a fragment of the full-length SARS-CoV-2 spike protein required for the SARS-CoV-2 spike protein to bind ACE2. The amino acid sequence of an exemplary reference SARS-CoV-2 spike protein RBD (of the full-length immature SARS- CoV-2 spike protein set forth in SEQ ID NO: 1) is set forth in SEQ ID NO: 5. The amino acid sequence of an exemplary mature human ACE2 protein is set forth in SEQ ID NO: 78. The terms “RNA” and “polyribonucleotide” are used interchangeably herein and refer to macromolecules that include multiple ribonucleotides that are polymerized via phosphodiester bonds. Ribonucleotides are nucleotides in which the sugar is ribose. RNA may contain modified nucleotides; and contain natural, non-natural, or altered internucleotide linkages, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule. As used herein, the term “SARS-CoV-2 spike” protein refers to the SARS-CoV-2 protein that mediates binding to the host cell receptor angiotensin-converting enzyme 2 (ACE2). An exemplary amino acid sequence of a reference immature SARS-CoV-2 spike protein is set forth in SEQ ID NO: 1. The term SARS-CoV-2 spike protein includes naturally occurring and engineered variants. As used herein, the term “set” with reference to amino acid variation(s) (e.g., substitution(s)) does not require more than one amino acid variation (e.g., substitution). For example, Table 2 and Table 4 herein describe “sets” of amino acid substitutions, some sets have only one amino acid substitution and some sets have more than one amino acid substitution. As used herein, the term “signal peptide” or “signal sequence” refers to a sequence (e.g., an amino acid sequence) that can direct the transport or localization of a protein to a certain organelle, cell compartment, or extracellular export. The term encompasses both the signal peptide (the amino acid sequence of the signal peptide) and the nucleic acid sequence encoding the signal peptide. Thus, references to a signal peptide in the context of a nucleic acid molecule refers to the nucleic acid sequence encoding the signal peptide. As used herein, the term “subject” includes any animal, such as a human or other animal. In embodiments, the subject is a vertebrate animal (e.g., mammal, bird, fish, reptile, or Attorney Docket No.62801.16WO01 amphibian). In embodiments, the subject is a human. In embodiments, the method subject is a non-human mammal. In embodiments, the subject is a non-human mammal is such as a non- human primate (e.g., monkeys, apes), ungulate (e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys), carnivore (e.g., dog, cat), rodent (e.g., rat, mouse), or lagomorph (e.g., rabbit). In embodiments, the subject is a bird, such as a member of the avian taxa Galliformes (e.g., chickens, turkeys, pheasants, quail), Anseriformes (e.g., ducks, geese), Paleaognathae (e.g., ostriches, emus), Columbiformes (e.g., pigeons, doves), or Psittaciformes (e.g., parrots). A “therapeutically effective amount” of an agent (e.g., a therapeutic agent, a vaccine) refers to any amount of the agent (e.g., the therapeutic agent, the vaccine) that, when used alone or in combination with another agent (e.g., a therapeutic agent, a vaccine), protects a subject against the onset of a disease (e.g., an infection), ameliorates the severity of a disease (e.g., an infection), and / or promotes disease (e.g., infection) regression evidenced by a decrease in severity of disease (e.g., infection) symptoms, an increase in frequency and duration of disease (e.g., infection) symptom-free periods, or a prevention of impairment or disability due to the disease (e.g., infection) affliction. The ability of an agent (e.g., a therapeutic agent, a vaccine) to do any of the foregoing (or any combination thereof) can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays. As used herein, the term “translatable RNA” refers to any RNA that encodes at least one polypeptide or protein and can be translated to produce the encoded polypeptide or protein in vitro, in vivo, in situ or ex vivo. A translatable RNA may be an mRNA or a circular RNA encoding a polypeptide or protein. As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing or ameliorating a disease or infection and / or symptom(s) associated therewith or obtaining a desired pharmacologic and / or physiologic effect. It will be appreciated that, although not precluded, treating a disease or infection does not require that the disease or infection, or symptom(s) associated therewith be completely eliminated. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, decreases the intensity of, or cures a disease and / or adverse symptom attributable to the disease or infection. In some embodiments, the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a Attorney Docket No.62801.16WO01 disease or infection. To this end, the presently disclosed methods comprise administering a therapeutically effective amount of a compositions as described herein. As used herein, the term “variant” or “variation” with reference to a nucleic acid molecule, refers to a nucleic acid molecule that comprises at least one substitution, alteration, inversion, addition, or deletion of nucleotide compared to a reference nucleic acid molecule. As used herein, the term “variant” or “variation” with reference to a peptide or protein refers to a peptide or protein that comprises at least one substitution, alteration, inversion, addition, or deletion of an amino acid residue compared to a reference peptide or protein. As used herein, the term “5’-untranslated region” or “5’-UTR” refers to a part of a nucleic acid molecule located 5’ (i.e., “upstream”) of a coding sequence and which is not translated into protein. Typically, a 5’-UTR starts with the transcriptional start site and ends before the start codon of the coding sequence. A 5’-UTR may comprise elements for controlling gene expression, also called regulatory elements. Such regulatory elements may be, e.g., ribosomal binding sites, miRNA binding sites etc. The 5’-UTR may be post- transcriptionally modified, e.g., by enzymatic or post-transcriptional addition of a 5’-cap structure. As used herein the term “3’-untranslated region” or “3’-UTR” refers to a part of a nucleic acid molecule located 3’ (i.e., downstream) of a coding sequence and which is not translated into protein. A 3’-UTR may located between a coding sequence and an (optional) terminal poly(A) sequence of a nucleic acid sequence. A 3'-UTR may comprise elements for controlling gene expression, also called regulatory elements. Such regulatory elements may be, e.g., ribosomal binding sites, miRNA binding sites etc. 5.2 SARS-CoV-2 Spike Proteins (e.g., Immunogens) The SARS-CoV-2 spike protein mediates viral entry into host cells. The spike protein comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and fusion of the viral and cellular membranes (S2 subunit). The SARS-CoV-2 spike protein is cleaved at the boundary between the S1 and S2 subunits, which remain non- covalently associated in the prefusion conformation. The distal S1 subunit comprises the RBD and contributes to stabilization of the prefusion state of the membrane anchored S2 subunit that contains the fusion machinery. The RBD mediates binding to the host cell receptor ACE2. The spike protein is cleaved by host proteases at the so-called S2’ site located immediately upstream of the fusion peptide. This cleavage has been proposed to activate the protein for membrane fusion via extensive irreversible conformational changes. (See, e.g., Walls, Alexandra C et al. Attorney Docket No.62801.16WO01 “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.” Cell vol. 181,2 (2020): 281-292.e6. doi:10.1016 / j.cell.2020.02.058, the entire contents of which is incorporated herein by reference for all purposes). The amino acid sequence of a first reference immature SARS-CoV-2 spike protein is provided in SEQ ID NO: 1. The signal peptide is underlined (amino acids 1-13 of SEQ ID NO: 1); the amino acid sequence of the corresponding mature first reference SARS-CoV-2 spike protein lacking the native signal peptide is provided in SEQ ID NO: 2. The amino acid sequence of an exemplary RBD of the first reference SARS-CoV-2 spike protein is set forth in SEQ ID NO: 5. The amino acid sequence of a second reference immature SARS-CoV-2 spike protein is provided in SEQ ID NO: 3. The signal peptide is underlined (amino acids 1-13 of SEQ ID NO: 3); the amino acid sequence of the corresponding mature second reference SARS- CoV-2 spike protein lacking the native signal peptide is provided in SEQ ID NO: 4. The amino acid sequence of the second reference SARS-CoV-2 spike protein comprises a proline at amino acid positions 986 and 987, amino acid numbering relative to SEQ ID NO: 1. This diproline amino acid substitution stabilizes said SARS-CoV-2 spike protein in a prefusion state. The amino acid sequence of an exemplary RBD of the second reference SARS-CoV-2 spike protein is set forth in SEQ ID NO: 5. The amino acid sequence of a third reference immature SARS-CoV-2 spike protein is provided in SEQ ID NO: 6. The signal peptide is underlined (amino acids 1-13 of SEQ ID NO: 6); the amino acid sequence of the corresponding mature third reference SARS-CoV-2 spike protein lacking the native signal peptide is provided in SEQ ID NO: 7. The amino acid sequence of an exemplary RBD of the third reference SARS-CoV-2 spike protein is set forth in SEQ ID NO: 10. The amino acid sequence of a fourth reference immature SARS-CoV-2 spike protein is provided in SEQ ID NO: 8. The signal peptide is underlined (amino acids 1-13 of SEQ ID NO: 8); the amino acid sequence of the corresponding mature fourth reference SARS- CoV-2 spike protein lacking the native signal peptide is provided in SEQ ID NO: 9. The fourth reference SARS-CoV-2 spike protein comprises a proline at amino acid positions 986 and 987, amino acid numbering relative to SEQ ID NO: 1. This diproline amino acid substitution stabilizes said SARS-CoV-2 spike protein in a prefusion state. The amino acid sequence of an exemplary RBD of the fourth reference SARS-CoV-2 spike protein is set forth in SEQ ID NO: 10. Attorney Docket No.62801.16WO01 The amino acid sequence of an exemplary reference human ACE2 (hACE2) proteins is also set forth in SEQ ID NO: 77 (immature) and SEQ ID NO: 78 (mature). Table 1. Amino Acid Sequence of Reference SARS-CoV-2 Spike Proteins (and Exemplary RBDs Thereof) and hACE2 Description Amino Acid Sequence SEQ ID NO Attorney Docket No.62801.16WO01 TGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDI TPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQ LTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAG Attorney Docket No.62801.16WO01 TIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH YT Attorney Docket No.62801.16WO01 CDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAE NSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYIC GDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQ Attorney Docket No.62801.16WO01 KVCEFQFCNDPFLDVYYHKNNKSWMESEFRVYSSANNCTFE YVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI NLGRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTP Attorney Docket No.62801.16WO01 CDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDL GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE QYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCC t s standard n te art to number te amno acd postons wt n a gven S S- CoV-2 spike protein (or polypeptide) according to the corresponding amino acid position in Attorney Docket No.62801.16WO01 the Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1). As such, unless otherwise indicated, the designation of amino acid positions in the amino acid sequence of a SARS-Cov- 2 spike protein (or polypeptide) (e.g., a SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) herein is relative to the amino acid sequence of SEQ ID NO: 1. A person of ordinary skill in the art can determine the corresponding amino acid for a given amino acid position by (i) aligning the amino acid sequence of the Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1) to the amino acid sequence of the query spike protein, (ii) locating the relevant amino acid position in the Wuhan-Hu-1 Spike reference sequence, and (iii) determining the amino acid located at the corresponding amino acid position in the query spike protein. As query spike proteins may have for example, insertions or deletions of amino acids relative to the Wuhan-Hu-1 Spike reference sequence, the amino acid corresponding to a particular position in the Wuhan-Hu-1 Spike reference sequence may not have the same amino acid number if one were to simply count the number of amino acids within the query spike protein. For example, FIGS. 1A-1C shows an alignment of the Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1) to the amino acid sequence of a query spike protein (SEQ ID NO: 6). The query spike protein comprises, inter alia, a deletion of five amino acids relative to the Wuhan-Hu-1 Spike reference sequence (amino acids L24, P25, P26, H69, and V70). However, the alignment keeps the corresponding amino acids in the query spike protein (SEQ ID NO: 6) correctly aligned to the Wuhan-Hu-1 Spike reference sequence. For example, if one wanted to locate amino acid position termed 339 in a query spike protein (e.g., SEQ ID NO: 6), one would generate the alignment in FIGS. 1A-1C, locate amino acid position 339 in the Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1) and subsequently locate the corresponding amino acid in the query spike protein (SEQ ID NO: 6), in this example position 339 (according to Wuhan-Hu-1 Spike reference sequence (SEQ ID NO: 1) numbering) in the query spike protein (SEQ ID NO: 6) is aspartic acid (D). This numbering system is indicated throughout the present disclosure by noting, “amino acid numbering relative to SEQ ID NO: 1” (or the like) and as “the Wuhan-Hu-1 Numbering System”. Although amino acid positions of the SARS-CoV-2 spike protein (or polypeptide) are defined herein relative to the full-length immature SARS-Cov-2 spike protein that contains the native signal sequence; it should be understood that this does not require the SARS-Cov-2 spike proteins (or polypeptides) (e.g., the SARS-CoV-2 spike protein immunogens (or Attorney Docket No.62801.16WO01 immunogenic fragments and / or immunogenic variants thereof)) described herein to include a native signal sequence. As outlined above, provided herein are, inter alia, SARS-CoV-2 spike proteins (and polypeptides) (e.g., SARS-CoV-2 spike protein and polypeptide immunogens (and immunogenic fragments and / or immunogenic variants thereof)) and nucleic acid molecules encoding the same, that comprise at least one amino acid substitution (e.g., one set of amino acid substitutions described herein, see, e.g., Table 2 and Table 4). Further provided herein are SARS-CoV-2 spike proteins (and polypeptides) (e.g., SARS-CoV-2 spike protein and polypeptide immunogens (and immunogenic fragments and / or immunogenic variants thereof)) and nucleic acid molecules encoding the same, that comprise any combination of amino acid substitutions described herein (see, e.g., Table 2 and Table 4), e.g., at least one set of amino acid substitutions described in Table 2 and at least one set of amino acid substitutions described in Table 4; at least two sets of amino acid substitutions described in Table 2; at least two sets of amino acid substitutions described in Table 4, etc. While, exemplary amino acid substitutions are provided herein, for example in Table 2 and Table 4, that specify the parental amino acid and the substituted amino acid; it should be understood that the disclosure covers the substitution of any parental amino acid with the substituted amino acid. As such, the substitutions set forth herein (e.g., in Table 2 and Table 4) include the substitution of any parental amino acid with the substituted amino acid. For example, amino acid substitution Set A set forth in Table 2 includes the substitution of any amino acid with proline at amino acid position 486 (amino acid numbering is relative to SEQ ID NO: 1). While exemplary amino acid substitutions are provided herein, for example in Table 2 and Table 4, that specify the parental amino acid and the substituted amino acid; it is to be understood that the disclosure includes the substitution of any parental amino acid with the substituted amino acid or a physiochemically similar amino acid to the substituted amino acid set forth in Table 2 and Table 4. A person of ordinary skill in the art can determine which amino acids would be considered physiochemically similar to any given substituted amino acid set forth in Table 2 and Table 4 utilizing standard methods (e.g., based on the physiochemical properties (e.g., charge, polarity, etc.) of each amino acid). Some sets of amino acid substitutions included in one or more of the SARS-CoV-2 spike proteins (or polypeptides) (e.g., immunogens) described herein are provided in Table 2. The amino acid numbering set forth in Table 2 is relative to SEQ ID NO: 1 (i.e., the Wuhan- Hu-1 Numbering System). Attorney Docket No.62801.16WO01 Table 2. Sets of Amino Acid Substitutions of SARS-CoV-2 Spike Proteins (e.g., Immunogens) Set Amino Acid Substitutions Exemplary Amino Acid Relative to SEQ ID NO: 1 immunogen (a SARS-CoV-2 spike protein or polypeptide immunogen). In some embodiments, the SARS-CoV-2 spike protein or polypeptide comprises an immunogen (a SARS-CoV-2 spike protein or polypeptide immunogen). In some embodiments, the SARS-CoV-2 spike protein or polypeptide comprises of an immunogenic fragment of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide comprises an immunogenic variant of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen comprises an immunogenic fragment of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen comprises an immunogenic variant of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen comprises an immunogenic fragment of a SARS-CoV-2 spike protein immunogen. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen comprises an immunogenic variant of a SARS-CoV-2 spike protein immunogen. In some embodiments, the SARS-CoV-2 spike protein or polypeptide consists of an immunogenic fragment of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide consists of an immunogenic variant of a SARS- CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen comprises or consists of an immunogenic fragment of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen consists of an immunogenic variant of a SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide immunogen consists of an immunogenic fragment of a SARS-CoV-2 spike protein immunogen. In some embodiments, the SARS-CoV- Attorney Docket No.62801.16WO01 2 spike protein or polypeptide immunogen consists of an immunogenic variant of a SARS- CoV-2 spike protein immunogen. As defined herein, an immunogen refers to a substance that is capable of inducing an immune response (e.g., an adaptive immune response) in a subject (e.g., a human subject). The immunogenicity of a protein or polypeptide described herein (e.g., a SARS-CoV-2 spike protein or polypeptide) (or a nucleic acid molecule encoding the same) can be determined through standard in silico, in vitro, ex vivo, and in vivo assays known in the art. The type of immune response measured can be determined by a person of ordinary skill in the art, e.g., in some embodiments, an antibody based immune response and / or a T cell based immune response is evaluated. For example, a sample (e.g., a blood, cell) can be taken from a subject (e.g., an animal, human) post administration of the protein or polypeptide described herein (e.g., a SARS-CoV-2 spike protein or polypeptide) (or a nucleic acid molecule encoding the same) to be evaluated. The sample can be utilized to evaluate indicators of an immune response. For example, a blood (or serum) sample can be utilized to assess the level of antibodies that bind the antigen. Such binding can be assessed through standard ELISAs. The presence of neutralizing antibodies in the sample can also be assessed using standard assays, including, e.g., plaque reduction neutralization assays and microneutralization assays. The induction of a T-cell based immune response can be measured using standard assays known in the art, including, e.g., immunospot assays to assess cytokine production utilizing peptide stimulated peripheral blood mononuclear cells (PBMCs) from the subject. See, e.g., Corominas J. et al, Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomized, double-blind, non-inferiority phase IIb trial, The Lancet Regional Health Europe, Vol. 28 (100613) May 2023 DOI:https: / / doi.org / 10.1016 / j.lanepe.2023.100613; Limin D et al, Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus, Frontiers in Medicine, Vol 8 (2022) DOI=10.3389 / fmed.2021.793437; Hana M El Sahly and others, Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial, The Journal of Infectious Diseases, Volume 226, Issue 10, 15 November 2022, Pages 1731–1742, https: / / doi.org / 10.1093 / infdis / jiac188; the entire contents of each of which is incorporated herein by reference for all purposes. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, Attorney Docket No.62801.16WO01 or 6 of the sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-5. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or Attorney Docket No.62801.16WO01 immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike Attorney Docket No.62801.16WO01 protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide Attorney Docket No.62801.16WO01 (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, Attorney Docket No.62801.16WO01 or 6 of the sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-5. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or Attorney Docket No.62801.16WO01 immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike Attorney Docket No.62801.16WO01 protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide Attorney Docket No.62801.16WO01 (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 2, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. The amino acid sequence of exemplary SARS-CoV-2 spike proteins (e.g., immunogens) comprising at least one of the sets of amino acid substitutions set forth above in Table 2 is provided in Table 3. Table 3 provides the amino acid sequence of an exemplary RBD Attorney Docket No.62801.16WO01 (SEQ ID NOS: 11-16) and the full-length spike protein (immature SEQ ID NOS: 17-22 and mature SEQ ID NOS: 23-28) of six exemplary SARS-CoV-2 spike proteins (e.g., immunogens) (A-F). Table 3. Amino Acid Sequence of SARS-CoV-2 Vaccine Proteins (e.g., Immunogens) Descri RBD Amino SEQ Immature Full- Mature Full- Acid Sequence ID NO Leng SEQ SEQ ption th Amino Length Amino Acid Se uence ID NO Acid Se uence ID NO Attorney Docket No.62801.16WO01 TRAGCLIGAEHVNN GRDIADTTDAVR SYECDIPIGAGICA DPQTLEILDITP SYQTQTNSPRRARS CSFGGVSVITPG Attorney Docket No.62801.16WO01 AIVMVTIMLCCM TSCCSCLKGCCS CGSCCKFDEDDS Attorney Docket No.62801.16WO01 PTNFTISVTTEILP ADQLTPTWRVYS VSMTKTSVDCTMYI TGSNVFQTRAGC CGDSTECSNLLLQY LIGAEHVNNSYE Attorney Docket No.62801.16WO01 NITNLCPFGE MFVFLVLLPLVSSQ QCVNLTTRTQLP VFNATRFASV CVNLTTRTQLPPAY PAYTNSFTRGVY YAWNRKRISN TNSFTRGVYYPDKV YPDKVFRSSVLH Attorney Docket No.62801.16WO01 AVEQDKNTQEVFAQ YQTQTNSPRRAR VKQIYKTPPIKDFG SVASQSIIAYTM GFNFSQILPDPSKP SLGAENSVAYSN Attorney Docket No.62801.16WO01 GVSPTKLNDL SGTNGTKRFDNPVL NGTKRFDNPVLP CFTNVYADSF PFNDGVYFASTEKS FNDGVYFASTEK VIRGDEVRQI NIIRGWIFGTTLDS SNIIRGWIFGTT Attorney Docket No.62801.16WO01 LGDIAARDLICAQK TSVDCTMYICGD FNGLTVLPPLLTDE STECSNLLLQYG MIAQYTSALLAGTI SFCTQLNRALTG Attorney Docket No.62801.16WO01 GCVIAWNSNN LGVYYHKNNKSWME QFCNDPFLGVYY LDSKVGGNYN SEFRVYSSANNCTF HKNNKSWMESEF YLYRLFRKSN EYVSQPFLMDLEGK RVYSSANNCTFE Attorney Docket No.62801.16WO01 VTQNVLYENQKLIA IKDFGGFNFSQI NQFNSAIGKIQDSL LPDPSKPSKRSF SSTASALGKLQDVV IEDLLFNKVTLA Attorney Docket No.62801.16WO01 NGVEGFNCYF NLVRDLPQGFSALE FKNIDGYFKIYS PLQSYGFQPT PLVDLPIGINITRF KHTPINLVRDLP NGVGYQPYRV QTLLALHRSYLTPG QGFSALEPLVDL Attorney Docket No.62801.16WO01 LSRLDPPEAEVQID KFNGLTVLPPLL RLITGRLQSLQTYV TDEMIAQYTSAL TQQLIRAAEIRASA LAGTITSGWTFG n or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids of any SARS- CoV-2 protein set forth in Table 3. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the Attorney Docket No.62801.16WO01 SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any SARS-Cov-2 protein set forth in Table 3. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 11-28. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-28. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 11-16. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, Attorney Docket No.62801.16WO01 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-16. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 17-28. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-28. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 17-22. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-22. Attorney Docket No.62801.16WO01 In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 23-28. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises or consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 23-28. Additional sets of amino acid substitutions included in one or more of the SARS- CoV-2 spike proteins (e.g., immunogens) described herein are provided in Table 4. The amino acid numbering set forth in Table 4 are relative to a reference SARS-CoV-2 spike protein comprising the amino acid sequence of SEQ ID NO: 1 (i.e., the Wuhan-Hu-1 Numbering System). Table 4. Amino Acid Substitutions in SARS-CoV-2 Spike Proteins (e.g., Immunogens) SetAmino Acid Substitutions Exemplary Amino Acid SubstitutionsRelative to the amino acid sequence of SEQ ID NO:K  T_I46 Attorney Docket No.62801.16WO01 T 444Q_396T_468N K444Q_Y396T_I468N  U 346S_445D_396T_468N R346S_V445D_Y396T_I468N  or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide Attorney Docket No.62801.16WO01 (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more Attorney Docket No.62801.16WO01 variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-5. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) Attorney Docket No.62801.16WO01 but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, Attorney Docket No.62801.16WO01 or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Attorney Docket No.62801.16WO01 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment Attorney Docket No.62801.16WO01 and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of Attorney Docket No.62801.16WO01 the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-5. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than Attorney Docket No.62801.16WO01 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, Attorney Docket No.62801.16WO01 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-10. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of one or more variations that are not set forth in Table 4, relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 1-4 or 6-9. In some embodiments, other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, Attorney Docket No.62801.16WO01 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-4 or 6-9. The amino acid sequence of exemplary SARS-CoV-2 spike proteins (e.g., immunogens) comprising at least one of the sets of amino acid substitutions set forth above in Table 4 is provided in Table 5. Table 5 provides the amino acid sequence of exemplary receptor binding domain (SEQ ID NOS: 29-44) and the full-length spike protein (immature SEQ ID NOS: 45-60 and mature SEQ ID NOS: 61-76) of sixteen exemplary SARS-CoV-2 proteins (e.g., immunogens) (G-V). Table 5. Amino Acid Sequence of SARS-CoV-2 Vaccine Proteins (e.g., Immunogens) Descri RBD Amino SE Immature Full- Mature Full- Acid Q SEQ SEQ ption ID NO Length Amino Acid ID NO Length Amino ID NO Attorney Docket No.62801.16WO01 VCGPKKSTNLVKNK KCVNFNFNGLTGTG CVNFNFNGLTGTGV VLTESNKKFLPFQQ LTESNKKFLPFQQF FGRDIADTTDAVRD Attorney Docket No.62801.16WO01 NITNLCPFH MFVFLVLLPLVSSQ QCVNLITRTQSYTN EVFNATRFA CVNLITRTQSYTNS SFTRGVYYPDKVFR SVYAWNRKR FTRGVYYPDKVFRS SSVLHSTQDLFLPF Attorney Docket No.62801.16WO01 KNTQEVFAQVKQIY YKTPPIKYFGGFNF KTPPIKYFGGFNFS SQILPDPSKPSKRS QILPDPSKPSKRSF FIEDLLFNKVTLAD Attorney Docket No.62801.16WO01 GVGHQPYRV PRTFLLKYNENGTI ITDAVDCALDPLSE VVLSFELLH TDAVDCALDPLSET TKCTLKSFTVEKGI APATVCGPK KCTLKSFTVEKGIY YQTSNFRVQPTESI Attorney Docket No.62801.16WO01 FCGKGYHLMSFPQS SAPHGVVFLHVTYV APHGVVFLHVTYVP PAQEKNFTTAPAIC AQEKNFTTAPAICH HDGKAHFPREGVFV Attorney Docket No.62801.16WO01 CVNFNFNGLTGTGV VLTESNKKFLPFQQ LTESNKKFLPFQQF FGRDIADTTDAVRD GRDIADTTDAVRDP PQTLEILDITPCSF Attorney Docket No.62801.16WO01 SVYAWNRKR FTRGVYYPDKVFRS SSVLHSTQDLFLPF ISNCVADYS SVLHSTQDLFLPFF FSNVTWFHAISGTN VLYNFAPFF SNVTWFHAISGTNG GTKRFDNPVLPFND Attorney Docket No.62801.16WO01 QILPDPSKPSKRSF FIEDLLFNKVTLAD IEDLLFNKVTLADA AGFIKQYGDCLGDI GFIKQYGDCLGDIA AARDLICAQKFNGL Attorney Docket No.62801.16WO01 APATVCGPK KCTLKSFTVEKGIY YQTSNFRVQPTESI KST QTSNFRVQPTESIV VRFPNITNLCPFDE RFPNITNLCPFDEV VFNATRFASVYAWN Attorney Docket No.62801.16WO01 AQEKNFTTAPAICH HDGKAHFPREGVFV DGKAHFPREGVFVS SNGTHWFVTQRNFY NGTHWFVTQRNFYE EPQIITTDNTFVSG Attorney Docket No.62801.16WO01 GRDIADTTDAVRDP PQTLEILDITPCSF QTLEILDITPCSFG GGVSVITPGTNTSN GVSVITPGTNTSNQ QVAVLYQGVNCTEV Attorney Docket No.62801.16WO01 VLYNFAPFF SNVTWFHAISGTNG GTKRFDNPVLPFND AFKCYGVSP TKRFDNPVLPFNDG GVYFASTEKSNIIR TKLNDLCFT VYFASTEKSNIIRG GWIFGTTLDSKTQS Attorney Docket No.62801.16WO01 GFIKQYGDCLGDIA AARDLICAQKFNGL ARDLICAQKFNGLT TVLPPLLTDEMIAQ VLPPLLTDEMIAQY YTSALLAGTITSGW Attorney Docket No.62801.16WO01 RFPNITNLCPFHEV VFNATTFASVYAWN FNATTFASVYAWNR RTRISNCVADYSVL TRISNCVADYSVLY YNFAPFFAFKCYGV Attorney Docket No.62801.16WO01 NGTHWFVTQRNFYE EPQIITTDNTFVSG PQIITTDNTFVSGN NCDVVIGIVNNTVY CDVVIGIVNNTVYD DPLQPELDSFKEEL Attorney Docket No.62801.16WO01 GVSVITPGTNTSNQ QVAVLYQGVNCTEV VAVLYQGVNCTEVP PVAIHADQLTPTWR VAIHADQLTPTWRV VYSTGSNVFQTRAG Attorney Docket No.62801.16WO01 TKLNDLCFT VYFASTEKSNIIRG GWIFGTTLDSKTQS NVTADSFVI WIFGTTLDSKTQSL LLIVNNATNVVIKV RGNEVSQIA LIVNNATNVVIKVC CEFQFCNDPFLDVY Attorney Docket No.62801.16WO01 VLPPLLTDEMIAQY YTSALLAGTITSGW TSALLAGTITSGWT TFGAGAALQIPFAM FGAGAALQIPFAMQ QMAYRFNGIGVTQN Attorney Docket No.62801.16WO01 KRISNCVADYSVLY YNFAPFFAFKCYGV NFAPFFAFKCYGVS SPTKLNDLCFTNVT PTKLNDLCFTNVTA ADSFVIRGNEVSQI Attorney Docket No.62801.16WO01 CDVVIGIVNNTVYD DPLQPELDSFKEEL PLQPELDSFKEELD DKYFKNHTSPDVDL KYFKNHTSPDVDLG GDISGINASVVNIQ Attorney Docket No.62801.16WO01 VAIHADQLTPTWRV VYSTGSNVFQTRAG YSTGSNVFQTRAGC CLIGAEYVNNSYEC LIGAEYVNNSYECD DIPIGAGICASYQT Attorney Docket No.62801.16WO01 RGNEVSQIA LIVNNATNVVIKVC CEFQFCNDPFLDVY PGQTGNIAD EFQFCNDPFLDVYY YHKNNKSWMESEFR YNYKLPDDF HKNNKSWMESEFRV VYSSANNCTFEYVS Attorney Docket No.62801.16WO01 FGAGAALQIPFAMQ QMAYRFNGIGVTQN MAYRFNGIGVTQNV VLYENQKLIANQFN LYENQKLIANQFNS SAIGKIQDSLSSTA Attorney Docket No.62801.16WO01 PTKLNDLCFTNVTA ADSFVIRGNEVSQI DSFVIRGNEVSQIA APGQTGNIADYNYK PGQTGNIADYNYKL LPDDFTGCVIAWNS Attorney Docket No.62801.16WO01 KYFKNHTSPDVDLG GDISGINASVVNIQ DISGINASVVNIQK KEIDRLNEVAKNLN EIDRLNEVAKNLNE ESLIDLQELGKYEQ Attorney Docket No.62801.16WO01 LIGAEYVNNSYECD DIPIGAGICASYQT IPIGAGICASYQTQ QTKSHRRARSVASQ TKSHRRARSVASQS SIIAYTMSLGAENS so e e o e s, e a o ac sequece o e - o - sp e poe or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids of any SARS- Attorney Docket No.62801.16WO01 CoV-2 protein set forth in Table 5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any SARS-Cov-2 protein set forth in Table 5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide Attorney Docket No.62801.16WO01 immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 45-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other Attorney Docket No.62801.16WO01 than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV- 2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises no more than about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-1300, 10-1200, 10-1100, 10-1000, 10-900, 10-800, 10-700, 10-600, 10-500, 10-400, Attorney Docket No.62801.16WO01 10-500, 10-400, 10-300, 10-250, 10-200, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 10-1300, 20-1300, 30-1300, 40-1300, 50-1300, 60-1300, 70-1300, 80-1300, 90- 1300, 100-1300,10-250, 20-250, 30-250, 40-250, 50-250, 60-250, 70-250, 80-250, 90-250, or 100-250 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids of any SARS- CoV-2 protein set forth in Table 5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of any SARS-Cov-2 protein set forth in Table 5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, Attorney Docket No.62801.16WO01 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 45-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-76. Attorney Docket No.62801.16WO01 In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, or 1200 amino acids set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, and the other than the at least 1, 2, 3, 4, 5, or 6 of the sets of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61-76. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) consists of at least about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV- 2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of no more than about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of from about 10-1300, 10-1200, 10-1100, 10-1000, 10-900, 10-800, 10-700, 10-600, 10-500, 10-400, 10-500, 10-400, 10-300, 10-250, 10-200, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 10-1300, 20-1300, 30-1300, 40-1300, 50-1300, 60-1300, 70-1300, 80-1300, 90- 1300, 100-1300,10-250, 20-250, 30-250, 40-250, 50-250, 60-250, 70-250, 80-250, 90-250, or 100-250 amino acids. 5.2.1 Exemplary Additional Features of SARS-CoV-2 Spike Proteins (e.g., Immunogens) The SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) can exhibit additional structural and functional features. Exemplary additional structural and functional features are provided below. 5.2.1.1 Full-Length Spike Proteins and Receptor Binding Fragments In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the full-length SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of the full-length SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a fragment of the full-length SARS-CoV-2 spike protein that is capable of binding the ACE2 receptor. In some embodiments, the SARS-CoV- 2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen Attorney Docket No.62801.16WO01 (or immunogenic fragment and / or immunogenic variant thereof)) consists of a fragment of the full-length SARS-CoV-2 spike protein that is capable of binding the ACE2 receptor. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least a portion of a RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS- CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least a portion of a RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of a RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least a portion of the RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of at least a portion of the RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consists of the RBD of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the ectodomain of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the ectodomain of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or Attorney Docket No.62801.16WO01 immunogenic variant thereof)) does not include the transmembrane domain of the SARS-CoV- 2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) does not include the cytoplasmic domain of the SARS-CoV-2 spike protein. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) does not include the transmembrane domain or the cytoplasmic domain of the SARS-CoV-2 spike protein. 5.2.1.2 Stabilization In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is modified to improve stability of the protein produced. In some embodiments, the ectodomain of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is modified to improve stability of the protein produced. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation that stabilizes said SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in any one of SEQ ID NO: 1 that stabilizes the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at one or more of position 817, 892, 899, 986, and / or 987, amino acid numbering relative to the amino Attorney Docket No.62801.16WO01 acid positions set forth in SEQ ID NO: 1. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at positions 817, 892, 899, 986, and 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, or SEQ ID NO: 7 that stabilizes the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof))comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering amino acid numbering relative to SEQ ID NO: 1. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof))comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to SEQ ID NO: 1. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises an inactive furin cleavage site. In order to be able to trigger fusion, the spike protein of SARS-Cov-2 has to be cleaved into the S1 and S2 subunit. The cleavage site in SARS-Cov-2 is a polybasic motif (RRAR) (for example, amino acids 682- 685 of SEQ ID NO: 1) that can be activated by furin-like proteases. Modifications to the furin cleavage site that inactivate it are known in the art. See, e.g., Amanat F, Strohmeier S, Rathnasinghe R, et al. Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model. Preprint. bioRxiv. 2020;2020.09.16.300970. Published 2020 Sep 17. doi:10.1101 / 2020.09.16.300970 (describes the replacement of the RRAR cleavage site with a single alanine); and WO2022203963 (which describes the replacement of the RRAR cleavage site with the amino acid sequence QQAQ), the entire contents of each of which are incorporated by reference herein. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike Attorney Docket No.62801.16WO01 protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation in the furin cleavage site that inactivates the furin cleavage site. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a replacement of the RRAR cleavage site with a single alanine. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a replacement of the RRAR cleavage site with the amino acid sequence QQAQ. 5.2.1.3 Multimerization (e.g., Trimerization) Domains In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a multimerization (e.g., trimerization) domain. The multimerization domain (e.g., trimerization domain) facilities multimerization (e.g., trimerization) of the proteins upon expression in / from a cell. Suitable multimerization (e.g., trimerization) domains are known in the art, including e.g., a fibritin - based trimerization domain. This fibritin domain or ‘Foldon’ is derived from T4 fibritin and was previously described as an artificial natural trimerization domain. See, e.g., (Letarov et al., 1993) Biochemistry Moscow 64: 817- 823; S-Guthe et al., (2004) J. Mol. Biol. 337: 905-915). See, also, Meier et al., J Mol Biol. (2004) 344(4): 1051-69; WO 2018 / 081318; the entire contents of each of which are incorporated herein by reference for all purposes. 5.2.1.4 Engineered Glycosylation Sites In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site (e.g., compared to a reference protein). See, e.g., Lin Wei-Shuo et al., Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants, Frontiers in Immunology, (12) Article 795741, 02 December 2021, DOI=10.3389 / fimmu.2021.795741, the entire contents of which are incorporated herein by reference for all purposes. Attorney Docket No.62801.16WO01 In some embodiments, the inclusion of one or more non-naturally occurring glycosylation motif (e.g., N-glycosylation motif) comprising a non-naturally occurring glycosylation site facilitates glycan masking of an immunodominant epitope of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). In some embodiments, when the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is administered to a subject, the subject does not generate an effective number of neutralizing antibodies that specifically bind to the immunodominant epitope. Thus, in some embodiments, the inclusion of one or more non-naturally occurring glycosylation motif (e.g., N-glycosylation motif) comprising a non-naturally occurring glycosylation site shifts an immune response generated from the administration of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) to produce more neutralizing antibodies against the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 1In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 3. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one Attorney Docket No.62801.16WO01 or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the non-naturally occurring glycosylation motif is an N- linked glycosylation motif (e.g., NXT or NXS (wherein X is any amino acid except for proline)). In some embodiments, the non-naturally occurring glycosylation motif is an O-linked glycosylation motif (e.g., a serine or threonine). In some embodiments, the non-naturally occurring glycosylation site is an N-linked glycosylation site (an asparagine (N) residue within a N-linked glycosylation motif (e.g., NXT or NXS (wherein X is any amino acid except for proline)). In some embodiments, the non-naturally occurring glycosylation site is an O-linked glycosylation site (e.g., a serine or threonine). Glycosylation motifs are known in the art. For Attorney Docket No.62801.16WO01 example, NX1X2, wherein X1 can be any amino acid except for proline, and X2 can be S, T, or C, is known as a consensus N-glycosylation sequence. O-linked glycosylation motifs include single serine or threonine residues. 5.2.1.5 Hyperglycosylation In some embodiments, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) is hyper-glycosylated relative to a reference SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) (e.g., the SARS-CoV-2 spike protein set forth in SEQ ID NO: 1) (e.g., a SARS-CoV-2 spike protein that does not contain the one or more non-naturally occurring glycosylation sites). Standard methods known in the art can be utilized to evaluate the glycosylation of a protein or peptide, including e.g., the level of glycosylation, the sites of glycosylation, etc. See, e.g., Roth et al, Identification and Quantification of Protein Glycosylation (2012) International Journal of Carbohydrate Chemistry, Volume 201, Article ID 640923, https: / / doi.org / 10.1155 / 2012 / 640923; Lebede et al, Exploring the Chemical Space of Protein Glycosylation in Noncovalent Protein Complexes: An Expedition along Different Structural Levels of Human Chorionic Gonadotropin by Employing Mass Spectrometry, Anal. Chem. 2021, 93, 30, 10424–10434 (July 21, 2021) https: / / doi.org / 10.1021 / acs.analchem.1c02199; Leymarie et al., Effective Use of Mass Spectrometry for Glycan and Glycopeptide Structural Analysis, Anal. Chem. 2012, 84, 7, 3040–3048 (February 21, 2012) https: / / doi.org / 10.1021 / ac3000573the entire contents of each of which is incorporated by reference herein for all purposes. Standard methods include for example, the enzymatic or chemical release of glycans from the subject proteins followed by chromatography or mass spectrometry based structural analysis. Glycan site mapping is further standard in art through the use of enzymatic digestions and subsequent tandem mass spectrometry-based analysis. See, e.g., Roth et al, Identification and Quantification of Protein Glycosylation (2012) International Journal of Carbohydrate Chemistry, Volume 201, Article ID 640923, https: / / doi.org / 10.1155 / 2012 / 640923, the entire contents of which is incorporated by reference herein for all purposes. 5.2.1.6 Additional Variations In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises an amino acid sequence comprising at least 1, 2, 3, Attorney Docket No.62801.16WO01 4, 5, 6, 7, 8, 9, or 10 amino acid variants that are not listed in Table 2 or Table 4. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises an amino acid sequence comprising or consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid variants that are not listed in Table 2 or Table 4. In some embodiments, the amino acid variants not listed in Table 2 or Table 4 are found in one or more circulating variants of SARS-CoV-2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4. In some embodiments, the amino acid sequence of the SARS- CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein Attorney Docket No.62801.16WO01 or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5. In some embodiments, the amino acid variants not listed in Table 2 or Table 4 are found in one or more circulating variants of SARS-CoV-2. 5.2.1.7 Variations from Different Strains of SARS-CoV-2 In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein is derived from a circulating strain (i.e., naturally occurring variant) of SARS-CoV-2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein comprises one or more amino acid variation found in one or more circulating variants of SARS-CoV-2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein is derived from a strain of SARS-CoV-2 known to have previously circulated. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein comprises one or more amino acid variation found in one or more SARS-CoV-2 variants known to have previously circulated. For example, in some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein comprises a glycine at position 614, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO: 1. 5.3 Nucleic Acid Molecules Provided herein are, inter alia, nucleic acid molecules comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2). In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule (e.g., mRNA or circular RNA). In some embodiments, the nucleic acid (e.g., RNA) molecule is a translatable RNA. In some embodiments, the nucleic acid (e.g., RNA) molecule is an mRNA. In some embodiments, the nucleic acid (e.g., RNA) molecule is a circular RNA. In some embodiments, the nucleic acid molecule encoding the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) (e.g., described herein) comprises from about 30 to about 20000 nucleotides, about 50 to about 20000 nucleotides, Attorney Docket No.62801.16WO01 about 500 to about 10000 nucleotides, about 1000 to about 10000 nucleotides, about 1000 to about 5000 nucleotides, or about 2000 to about 5000 nucleotides. In some embodiments, the nucleic acid molecule encoding the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS- CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 30 nucleotides, 50 nucleotides, 100 nucleotides, 200 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 1000 nucleotides, 2000 nucleotides, 3000 nucleotides, or 5000 nucleotides. In some embodiments, the nucleic acid molecule is altered (e.g., compared to the sequence of a reference nucleic acid molecule, a naturally occurring nucleic acid molecule), e.g., to impart one or more of (a) improved resistance to in vivo degradation, (b) improved stability in vivo, (c) reduced secondary structures, and / or (d) improved translatability in vivo, compared to the reference nucleic acid sequence. Alterations include, without limitation, e.g., codon optimization, nucleotide modifications (see, e.g., described herein), etc. In some embodiments, the sequence of the nucleic acid molecule is codon optimized, e.g., for expression in humans. Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias guanosine (G) and / or cytosine (C) content to increase nucleic acid stability; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove / add post translation alteration sites in an encoded protein (e.g., glycosylation sites); add, remove, or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of a protein to fold properly; and / or to reduce or eliminate secondary structures (e.g., problem secondary structures) within the nucleic acid molecule. In some embodiments, the codon optimized nucleic acid sequence shows one or more of the above (compared to a reference nucleic acid sequence). In some embodiments, the codon optimized nucleic acid sequence shows one or more of improved resistance to in vivo degradation, improved stability in vivo, reduced secondary structures, and / or improved translatability in vivo, compared to a reference nucleic acid sequence. Codon optimization methods, tools, algorithms, and services are known in the art, non-limiting examples include services from GeneArt (Life Technologies) and DNA2.0 (Menlo Park Calif.). In some embodiments, the open reading frame (ORF) sequence is optimized using optimization algorithms (e.g., optimization algorithms known in the art). In some embodiments, the nucleic acid sequence is modified to optimize the number of G and / or C nucleotides as compared to a reference nucleic acid sequence. An increase in the Attorney Docket No.62801.16WO01 number of G and C nucleotides may be generated by substitution of codons containing adenosine (A) or thymidine (T) (or uracil (U)) nucleotides by codons containing G or C nucleotides. 5.3.1 DNA Molecules In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the DNA is a linear coding DNA construct. In some embodiments, the DNA contained within a vector (e.g., a non-viral vector (e.g., a plasmid) or a viral vector). In some embodiments, the DNA is contained within a non-viral vector (e.g., a plasmid). In some embodiments, the DNA is contained within a viral vector (e.g., described herein). A more detailed description of vectors for both RNA and DNA nucleic acids is provided in § 5.6. The DNA molecule may also comprise one or more heterologous nucleic acid elements to mediate expression of the coding region. These include, e.g., promoter(s), enhancer(s), polyadenylation signal(s), synthetic introns, transcriptional termination signals, polyadenylation sequences, and other transcription regulatory elements. A person of ordinary skill in the art is familiar with the transcriptional regulatory elements needed for expression of coding DNA can optimize the expression construct (e.g., linear DNA, plasmid DNA, etc.) accordingly. In some embodiments, a promoter is operably connected to the respective coding nucleic acid sequence. The person of ordinary skill in the art is aware of various promoters that can be employed, for example, a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter, bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter can also be a promoter from a human gene, for example, from human actin, human myosin, human hemoglobin, human muscle creatine, or human metalothionein. The promoter can also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic. Examples of such promoters are described in US Patent Application Publication No. US20040175727, the entire contents of which is incorporated by reference herein for all purposes. Exemplary polyadenylation signals, include, but are not limited, to the bovine growth hormone (BGH) polyadenylation site, SV40 polyadenylation signals, and LTR polyadenylation signals. Attorney Docket No.62801.16WO01 5.3.2 RNA Molecules In some embodiments, the nucleic acid molecule is an RNA molecule. In some embodiments, the RNA molecule is a translatable RNA molecule. In some embodiments, the RNA molecule is selected from an mRNA, a self-replicating RNA, a circular RNA, a viral RNA, or a replicon RNA. In some embodiments, the RNA molecule a circular RNA. Exemplary circular RNAs are described in e.g., US11458156, US20220143062, US20230212629, US20230072532, US11203767, US11352641, US20210371494, US11766449, US20230226096, WO2021189059, US20190345503, US20220288176, US11560567, WO2022271965, WO2022037692, WO2023024500, WO2023115732, WO2023133684, WO2023143541, WO2023134611, and WO2022247943, the entire contents of each of which are incorporated herein by reference for all purposes. In some embodiments, the RNA molecule is a mRNA. The basic components of an mRNA molecule typically include at least one coding region (herein a coding region encoding at least one peptide or protein (e.g., a SARS-CoV-2 protein (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or an immunogenic fragment and / or variant thereof)) (e.g., described herein), a 5’-untranslated region (UTR), a 3’-UTR, a 5’ cap, and a poly-A tail. In some embodiments, the RNA (e.g., mRNA) comprises at least one heterologous UTR. The UTRs may harbor regulatory sequence elements that determine the RNA (e.g., mRNA) turnover, stability, localization, and / or expression of operably connected coding sequence(s). The heterologous UTRs may be derived from a naturally occurring gene or may be synthetically engineered. In some embodiments, the 5’-UTR comprises elements for controlling gene expression, e.g., ribosomal binding sites, miRNA binding sites. The 5’-UTR may be post-transcriptionally modified, e.g., by enzymatic or post-transcriptional addition of a 5’cap structure. In some embodiments, the 3’-UTR comprises a polyadenylation signal. In some embodiments, the RNA (e.g., mRNA) comprises at least one coding region encoding the polypeptide or protein (e.g., a SARS-CoV-2 protein (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) (e.g., described herein) and 5’-UTR and / or a 3’-UTR. In some embodiments, the RNA (e.g., mRNA) comprises at least one coding sequence encoding a polypeptide or protein (e.g., a SARS-CoV-2 protein (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) (e.g., described herein) operably connected to at least one heterologous 5’-UTR and at least one 3’-UTR. Attorney Docket No.62801.16WO01 In some embodiments, the RNA (e.g., mRNA) comprises a poly(A) sequence. The poly(A) sequence may comprise from about 10 to 500 adenosine nucleotides, 10 to 200 adenosine nucleotides, 20 to 200 adenosine nucleotides, 30 to 200 adenosine nucleotides, 40 to 200 adenosine nucleotides, or 50 to 200 adenosine nucleotides. In some embodiments, poly(A) sequence comprises at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 adenosine nucleotides. The poly(A) sequence may comprise from about 10 to 500 adenosine nucleotides, 10 to 200 adenosine nucleotides, 20 to 200 adenosine nucleotides, 30 to 200 adenosine nucleotides, 40 to 200 adenosine nucleotides, or 50 to 200 adenosine nucleotides, wherein the 3’ terminal nucleotide of said nucleic acid molecule is an adenosine. In some embodiments, poly(A) sequence comprises at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, or 500 adenosine nucleotides, wherein the 3’ terminal nucleotide of said nucleic acid molecule is an adenosine. In some embodiments, the RNA (e.g., mRNA) comprises a 5’-cap structure. In some embodiments, the 5’-cap structure stabilizes the RNA (e.g., mRNA), enhances expression of the encoded polypeptide or protein (e.g., a SARS-CoV-2 protein (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) (e.g., described herein) and / or reduces the stimulation of the innate immune system (e.g., after administration to a subject). Exemplary 5’-cap structures include, but are not limited to, cap0 (methylation of the first nucleobase, e.g., m7GpppN), cap1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN), cap2 (additional methylation of the ribose of the 2nd nucleotide downstream of the m7GpppN), cap3 (additional methylation of the ribose of the 3rd nucleotide downstream of the m7GpppN), cap4 (additional methylation of the ribose of the 4th nucleotide downstream of the m7GpppN), ARCA (anti-reverse cap analogue), modified ARCA (e.g., phosphorothioate modified ARCA), inosine, N1-methyi-guanosine, 2'-fluoro-guanosine, 7- deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido- guanosine. In some embodiments, the 5’ cap structure comprises m7G, cap0, cap1, cap2, a modified capO, or a modified cap1 structure. In some embodiments, the RNA (e.g., mRNA) comprises one or more modified nucleotide (e.g., nucleotide analogue, backbone modifications, sugar modifications, and / or base modifications). A backbone modification in the context of the present disclosure is a modification, in which phosphates of the backbone of the nucleotides of the RNA (e.g., mRNA) are chemically modified. A sugar modification in the context of the present disclosure is a chemical modification of the sugar of the nucleotides of the RNA (e.g., mRNA). A base Attorney Docket No.62801.16WO01 modification in the context of the present disclosure is a chemical modification of the base moiety of the nucleotides of the RNA (e.g., mRNA). In some embodiments, the RNA (e.g., mRNA) comprises at least one modified nucleotide. Exemplary nucleotide analogues / modifications include, but are not limited to, 2- amino-6-chloropurineriboside-5’-triphosphate, 2-Aminopurine-riboside-5’-triphosphate; 2- aminoadenosine-5'-triphosphate, 2’-Amino-2’-deoxycytidine-triphosphate, 2-thiocytidine-5'- triphosphate, 2-thiouridine-5’-triphosphate, 2’-Fluorothymidine-5’-triphosphate, 2’-O- Methyl-inosine-5’-triphosphate 4-thiouridine-5’-triphosphate, 5-aminoallylcytidine-5’- triphosphate, 5-aminoallyluridine-5’-triphosphate, 5-bromocytidine-5’-triphosphate, 5- bromouridine-5’-triphosphate, 5-Bromo-2’-deoxycytidine-5'-triphosphate, 5-Bromo-2’- deoxyuridine-5'-triphosphate, 5-iodocytidine-5’-triphosphate, 5-lodo-2’-deoxycytidine-5'- triphosphate, 5-iodouridine-5’ -triphosphate, 5-lodo-2’-deoxyuridine-5’-triphosphate, 5- methylcytidine-5’-triphosphate, 5-methyluridine-5’-triphosphate, 5-Propynyl-2’- deoxycytidine-5’-triphosphate, 5-Propynyl-2'-deoxyuridine-5’-triphosphate, 6-azacytidine-5’- triphosphate, 6-azauridine-5’-triphosphate, 6-chloropurineriboside-5'-triphosphate, 7- deazaadenosine-5’-triphosphate, 7-deazaguanosine-5’-triphosphate, 8-azaadenosine-5’- triphosphate, 8-azidoadenosine-5’-triphosphate, benzimidazole-riboside-5’-triphosphate, N1- methyladenosine-5’-triphosphate, N1-methylguanosine-5’-triphosphate, N6-methyladenosine- 5'-triphosphate, O6-methylguanosine-5’-triphosphate, pseudouridine-5’-triphosphate, or puromycin-5’-triphosphate, xanthosine-5’-triphosphate. Particular preference is given to nucleotides for base modifications selected from the group of base-modified nucleotides consisting of 5-methylcytidine-5’-triphosphate, 7-deazaguanosine-5'-triphosphate, 5- bromocytidine-5’-triphosphate, and pseudouridine-5’-triphosphate, pyridin-4-one ribonucleoside, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2- thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyl-uridine, 1- carboxymethyl-pseudouridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5- taurinomethyluridine, 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uridine, 1- taurinomethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl- pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1- methyl-1-deaza-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy- pseudouridine, and 4-methoxy-2-thio-pseudouridine, 5-aza-cytidine, pseudoisocytidine, 3- methyl-cytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5- hydroxymethylcytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo- Attorney Docket No.62801.16WO01 pseudoisocytidine, 2 -thiocytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio- 1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza- pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy- pseudoisocytidine, and 4-methoxy-1-methyl-pseudoisocytidine, 2-aminopurine, 2, 6- diaminopurine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-aminopurine, 7-deaza-8- aza-2-aminopurine, 7-deaza-2, 6-diaminopurine, 7-deaza-8-aza-2, 6-diaminopurine, 1- methyladenosine, N6-methyladenosine, N6-isopentenyladenosine, N6-(cis- hydroxyisopentenyl)adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6- glycinylcarbamoyladenosine, N6-threonylcarbamoyladenosine, 2-methylthio-N6-threonyl carbamoyladenosine, N6,N6-dimethyladenosine, 7-methyladenine, 2-methylthio-adenine, and 2-methoxy-adenine, inosine, 1-methyl-inosine, wyosine, wybutosine, 7-deaza-guanosine, 7- deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7 -deaza-guanosine, 6-thio-7-deaza-8-aza- guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy- guanosine, 1 -methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo- guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio- guanosine, and N2,N2-dimethyl-6-thio-guanosine, 5’-O-(1-thiophosphate)-adenosine, 5’-O- (1-thiophosphate)-cytidine, 5’-O-(1-thiophosphate)-guanosine, 5’-O-(1-thiophosphatej- uridine, 5’-O-(1-thiophosphate)-pseudouridine, 6-aza-cytidine, 2-thio-cytidine, alpha-thio- cytidine, Pseudoiso-cytidine, 5-aminoallyl-uridine, 5-iodo-uridine, N1-methyl-pseudouridine, 5,6-dihydrouridine, alpha -thio-uridine, 4-thio-uridine, 6-aza-uridine, 5-hydroxy-uridine, deoxy-thymidine, 5-methyl-uridine, Pyrrolo-cytidine, inosine, alpha -thioguanosine, 6-methyl- guanosine, 5-methyl-cytdine, 8-oxo-guanosine, 7-deaza-guanosine, N1-methyl-adenosine, 2- amino-6-Chloro-purine, N6-methyl-2-amino-purine, Pseudo-iso-cytidine, 6-Chloro-purine, N6-methyl-adenosine, alpha -thioadenosine, 8-azido-adenosine, and 7-deaza-adenosine. In some embodiments, the RNA (e.g., mRNA) comprises pseudouridine, N1 - methylpseudouridine, N1-ethylpseudouridine, 2-thiouridine, 4’-thiouridine, 5-methylcytosine, 5-methyluridine, 2-thio-1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-pseudouridine, 2- thio-5-aza-uridine, 2-thio-dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-pseudouridine, 4-methoxy-2-thio-pseudouridine, 4-methoxy-pseudouridine, 4-thio-1-methyl-pseudouridine, 4-thio-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methoxyuridine, and / or 2’-O- methyl uridine. In some embodiments, the RNA (e.g., mRNA) comprises one or more pseudouridine (ψ), N 1 -methylpseudouridine (m1ψ), 5-methylcytosine, and 5-methoxyuridine. Attorney Docket No.62801.16WO01 In some embodiments, essentially all, e.g., essentially 100% of the uracil in the coding sequence of the RNA (e.g., mRNA) have a chemical modification, preferably a chemical modification is in the 5-position of the uracil. Incorporating modified nucleotides such as e.g., pseudouridine (ψ), N1 -methylpseudouridine (m1ψ), 5-methylcytosine, and / or 5- methoxyuridine into the coding sequence may be advantageous as unwanted innate immune responses (upon administration of the coding RNA or the vaccine) may be adjusted or reduced (if required). In one embodiment, the RNA (e.g., mRNA) comprises: (i) a 5'-cap structure; (ii) a 5'-UTR; (iii) N1-methyl-pseudouridine, cytosine, adenine, and guanine; (iv) a 3'-UTR; and (v) a poly-A region. RNA (e.g., mRNA) described herein can be generated by e.g., in vitro transcription. In vitro transcription is a method well known to those of ordinary skill in the art for the production of RNA (e.g., mRNA). Generally, the RNA is obtained by DNA-dependent in vitro transcription of an appropriate DNA template, e.g., a linearized plasmid DNA template or a PCR-amplified DNA template. The promoter for controlling RNA in vitro transcription can be any promoter for any DNA-dependent RNA polymerase. Examples of DNA-dependent RNA polymerases include the 17, T3, SP6, or Syn5 RNA polymerases. In some instances, the DNA template is linearized with a suitable restriction enzyme before it is subjected to RNA in vitro transcription. Reagents used in RNA in vitro transcription typically include: a DNA template (linearized plasmid DNA or PCR product) with a promoter sequence that has a high binding affinity for its respective RNA polymerase such as bacteriophage-encoded RNA polymerases (T7, T3, SP6, or Syn5); ribonucleotide triphosphates (NTPs) for the four bases (adenine, cytosine, guanine and uracil); a DNA-dependent RNA polymerase capable of binding to the promoter sequence within the DNA template (e.g., T7, T3, SP6, or Syn5 RNA polymerase); optionally, a ribonuclease (RNase) inhibitor to inactivate any potentially contaminating RNase; optionally, a pyrophosphatase to degrade pyrophosphate, which may inhibit RNA in vitro transcription; MgCh, which supplies Mg2+ ions as a co-factor for the polymerase; a buffer (TRIS or HEPES) to maintain a suitable pH value, which can also contain antioxidants (e.g., DTT), and / or polyamines such as spermidine at optimal concentrations, e.g., a buffer system comprising TRIS-Citrate as disclosed in W02017109161. The obtained RNA (e.g., mRNA) products can be purified according to methods known in the art. For example, using PureMessenger® (CureVac, Tubingen, Germany; RP-HPLC according to W02008077592) and / or tangential flow filtration (as described in WO2016193206) and / or oligo d(T) purification (see WO2016180430); or using RP-HPLC, e.g., using Reversed-Phase High Attorney Docket No.62801.16WO01 pressure liquid chromatography (RP-HPLC), the entire contents of each reference is incorporated by reference herein for all purposes. 5.4 Fusions & Conjugates In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2) or the nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.3) is operably connected to a heterologous moiety (e.g., a heterologous polypeptide) forming a fusion protein or polypeptide or conjugate. In some embodiments, the heterologous moiety (e.g., a heterologous polypeptide) imparts an additional function to the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). For example, a heterologous moiety (e.g., a heterologous polypeptide) may function to promote or improve secretion of the encoded SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)), (e.g., via secretory signal peptides); promote or improve anchoring of the encoded SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein in the plasma membrane (e.g., via transmembrane elements); promote or improve formation of antigen complexes (e.g., via multimerization domains or antigen clustering elements); and / or promote or improve virus-like particle formation (VLP forming sequence); improve half-life of the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). In some embodiments, the heterologous moiety is a half-life extension moiety. Exemplary half-life extension moieties include, but are not limited to, an immunoglobulins (e.g., immunoglobulin constant regions and fragment thereof) (e.g., human immunoglobulin (hIg), a fragment of a hIg, a hIg constant region, a fragment of a hIg constant region, a hIg Fc region), human transferrin, human serum albumin (HSA), an HSA binding protein, and polyethylene glycol (PEG) (and polymers thereof). In some embodiments, the heterologous polypeptide is a half-life extension polypeptide. Exemplary half-life extension polypeptides Attorney Docket No.62801.16WO01 include, but are not limited to, an immunoglobulins (e.g., immunoglobulin constant regions and fragment thereof) (e.g., human immunoglobulin (hIg), a fragment of a hIg, a hIg constant region, a fragment of a hIg constant region, a hIg Fc region), human transferrin, human serum albumin (HSA), and an HSA binding protein. The SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) or a nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) fused or conjugated to a half-life extending moiety (e.g., a half-life extension polypeptide) can be evaluated for their pharmacokinetic properties utilizing standard in vivo methods known in the art. In some embodiments, the heterologous moiety is a detectable agent (e.g., protein, e.g., a fluorescent protein). In some embodiments, the heterologous moiety (e.g., heterologous polypeptide) is a signal peptide. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a homologous signal peptide. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a heterologous signal peptide. In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., the SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) does not contain a signal peptide. In some embodiments, the heterologous moiety (e.g., heterologous polypeptide) is a multimerization element (e.g., trimerization element) (e.g., described herein). The heterologous moiety (e.g., heterologous polypeptide) can be directly operably connected or indirectly operably connected to the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) or the nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). In some embodiments, the heterologous moiety is directly operably connected to the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) or the nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic Attorney Docket No.62801.16WO01 fragment and / or immunogenic variant thereof)). In some embodiments, the heterologous moiety is indirectly operably connected to the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) or the nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)). A person of ordinary skill in the art can evaluate and select a suitable linker for the fusion or conjugation of a specific heterologous moiety. For example, in embodiments, wherein the heterologous moiety comprises a heterologous polypeptide, a peptide linker may be employed. Peptide linkers are known in the art and can be selected based on specific properties, including e.g., length, flexibility, rigidity, cleavability, etc. The amino acid sequence of commonly employed peptide linkers comprises glycine amino acid residues, serine amino acid residues, glycine and serine amino acid residues, or glycine, serine, and proline amino acid residues. The heterologous moiety (e.g., heterologous polypeptide) and the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) or the nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) can be arranged in orientation so long as each functional part of the fusion protein or polypeptide or conjugate maintains the ability to mediate its function. 5.5 Vaccine Compositions In some embodiments, a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS- CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2) (or a fusion or conjugate thereof (see, e.g., § 5.4)) or a nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.3) (or a fusion or conjugate thereof (see, e.g., § 5.4)) forms the basis for a vaccine composition (e.g., a prime vaccine composition, a vaccine booster composition, a vaccine prime and booster composition). Therefore, provided herein are, inter alia, vaccine compositions (e.g., prime vaccine compositions, vaccine booster compositions, vaccine prime and booster compositions) comprising at least one SARS-CoV-2 spike protein or polypeptide Attorney Docket No.62801.16WO01 (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2) (or a fusion or conjugate thereof (see, e.g., § 5.4)) or a nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.3) (or a fusion or conjugate thereof (see, e.g., § 5.4)). In some embodiments, the vaccine composition is a prime vaccine composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine booster composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine prime and booster composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition can be utilized as a prime and / or a booster (e.g., as described herein). In some embodiments, the vaccine composition forms a single dose vaccine that does not require a booster. 5.5.1 Peptide and Protein-Based Vaccines In some embodiments, a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS- CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2) (or a fusion or conjugate thereof (see, e.g., § 5.4)) forms the basis for a vaccine composition (e.g., a prime vaccine composition, a vaccine boost composition, a vaccine prime and booster composition). Therefore, provided herein are, inter alia, vaccine compositions (e.g., prime vaccine compositions, vaccine boost compositions, vaccine prime and booster compositions) comprising at least one SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.2) (or a fusion or conjugate thereof (see, e.g., § 5.4)). In some embodiments, the vaccine composition is a prime vaccine composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine boost composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine prime and booster composition of a prime-boost vaccine regimen. In some embodiments, the prime boost composition can be utilized as a prime and / or a booster (e.g., as described herein). In some embodiments, the vaccine composition forms a single dose vaccine that does not require a booster. Attorney Docket No.62801.16WO01 In some embodiments, the vaccine composition comprises a plurality of SARS- CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)). In some embodiments, the plurality comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)). In some embodiments, the plurality comprises from about 2-100, 2-90, 2- 80, 2-70, 2-60, 2-50, 2-40, 2-30, 2-20, 2-10, 2-5, 5-100, 5-90, 5-80, 5-70, 5-60, 5-50, 5-40, 5- 30, 5-20, 5-10, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 20-100, 20- 90, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 30-100, 30-90, 30-80, 30-70, 30-60, 30-50, 30- 40, 40-100, 40-90, 40-80, 40-70, 40-60, 40-50, 50-100, 50-90, 50-80, 50-70, 50-60, 60-100, 60-90, 60-80, 60-70, 70-100, 70-90, 70-80, 80-100, 80-90, or 90-100 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)). In some embodiments, the plurality comprises at least 2 but no more than 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 SARS- CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments or immunogenic variants thereof)). In some embodiments, the amino acid sequence of each of the SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the plurality is different. In some embodiments, the amino acid sequence of at least one of the SARS-CoV- 2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the plurality is derived from a circulating strain of SARS- CoV-2. In some embodiments, the plurality comprises at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein. In some embodiments, the plurality comprises at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein, wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the plurality comprises at least two SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic Attorney Docket No.62801.16WO01 variants thereof)) described herein, wherein the amino acid sequence of each of the at least two SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 2 or Table 4 or a different combination of sets of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the amino acid sequence of each of the SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the plurality comprises a different set of amino acid substitutions described herein (e.g., in Table 2 or Table 4) or a different combination of sets of amino acid substitutions described herein (e.g., in Table 2 or Table 4). In some embodiments, the plurality comprises (a) at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2; (b) at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4; and / or (c) at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4. In some embodiments, plurality comprises at least 2, 3, 4, 5, or 6 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)), wherein the amino acid sequence of each of said 2, 3, 4, 5, or 6 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 2 or a different combination of sets of amino acid substitutions set forth in Table 2. In some embodiments, the plurality comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or Attorney Docket No.62801.16WO01 immunogenic fragments and / or immunogenic variants thereof)), wherein the amino acid sequence of each of the 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 4 or a different combination of sets of amino acid substitutions set forth in Table 4. In some embodiments, plurality comprises (a) at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2; and (b) at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the at least one SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4. In some embodiments, the plurality comprises (a) at least 2, 3, 4, 5, or 6 SARS- CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)), wherein the amino acid sequence of each of the 2, 3, 4, 5, or 6 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 2 or a different combination of sets of amino acid substitutions set forth in Table 2; and (b) at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)), wherein the amino acid sequence of each of said 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 4 or a different combination of sets of amino acid substitutions set forth in Table 4. In some embodiments, the composition further comprises a (e.g., at least one) SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)), that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4. In some embodiments, the amino acid sequence of the SARS-CoV- 2 spike protein is derived from a circulating strain of SARS-CoV-2. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein comprises one or more amino acid variation found in one or more circulating variants of SARS-CoV-2. In some embodiments, Attorney Docket No.62801.16WO01 the amino acid sequence of the SARS-CoV-2 spike protein is derived from a strain of SARS- CoV-2 known to have previously circulated. In some embodiments, the amino acid sequence of the SARS-CoV-2 spike protein comprises one or more amino acid variation found in one or more SARS-CoV-2 variants known to have previously circulated. In some embodiments, the vaccine composition further comprises at least one immunogen (or immunogenic fragment and / or immunogenic variant thereof) from a non- SARS-CoV-2 virus, e.g., an influenza virus (e.g., influenza A, influenza B), a respiratory syncytial virus (RSV), a rhinovirus, a parvovirus, a parainfluenza virus, an adenovirus. In some embodiments, vaccine composition comprises one or more immunogen (or immunogenic fragment or immunogenic variant thereof) from an influenza virus (e.g., influenza A, influenza B), a respiratory syncytial virus (RSV), a rhinovirus, a parvovirus, a parainfluenza virus, and / or an adenovirus (or any combination thereof). In some embodiments, the SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) (e.g., ectodomain of the SARS-CoV-2 spike protein or polypeptide) is modified to improve expression of the protein in host cells (e.g., insect cells, mammalian cells, eggs) as described below. Polypeptides and proteins (e.g., immunogens) described herein, e.g., SARS-CoV-2 spike proteins and polypeptides (e.g., immunogens (and immunogenic fragments and / or immunogenic variants thereof)) may be produced by recombinant technology in host cells (e.g., insect cells, mammalian cells, bacteria) that have been transfected or transduced with a nucleic acid expression vector (e.g., plasmid, viral vector (e.g., a baculoviral expression vector)) encoding the SARS-CoV-2 spike protein or polypeptide (e.g., the immunogen (or the immunogenic fragment and / or immunogenic variant thereof)). Such general methods are common knowledge in the art. The expression vector typically contains an expression cassette that includes nucleic acid sequences capable of bringing about expression of the nucleic acid molecule encoding the SARS-CoV-2 spike protein or polypeptide (e.g., the immunogen (or the immunogenic fragment and / or immunogenic variant thereof)), such as promoter(s), enhancer(s), polyadenylation signals, and the like. The person of ordinary skill in the art is aware that various promoter and enhancer elements can be used to obtain expression of a nucleic acid molecule in a host cell. For example, promoters can be constitutive or regulated, and can be obtained from various sources, e.g., viruses, prokaryotic or eukaryotic sources, or artificially designed. Post transfection or transduction, host cells containing the expression vector encoding the SARS-CoV-2 spike protein or polypeptide (e.g., the immunogen (or the Attorney Docket No.62801.16WO01 immunogenic fragment and / or immunogenic variant thereof)) are cultured under conditions conducive to expression of the nucleic acid molecule encoding the SARS-CoV-2 spike protein or polypeptide (e.g., the immunogen (or the immunogenic fragment and / or immunogenic variant thereof)). Culture media is available from various vendors, and a suitable medium can be routinely chosen for a host cell to express a polypeptide or protein of interest, here the SARS-CoV-2 spike protein or polypeptide (e.g., the immunogen (or the immunogenic fragment and / or immunogenic variant thereof)). Host cells can be adherent or suspension cultures, and a person of ordinary skill in the art can optimize culture methods for specific host cells selected. For example, suspension cells can be cultured in, for example, bioreactors in e.g., a batch process or a fed-batch process. The produced immunogenic peptide or protein may be isolated from the cell cultures, by, for example, column chromatography in either flow-flow through or bind-and-elute modes. Examples include, but are not limited to, ion exchange resins and affinity resins, such as lentil lectin Sepharose, and mixed mode cation exchange- hydrophobic interaction columns (CEX-HIC). The peptide or protein may be concentrated, buffer exchanged by ultrafiltration, and the retentate from the ultrafiltration may be filtered through an appropriate filter, e.g., a 0.22µm filter. See, e.g., McPherson et al., “Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant,” Chapter 4, in Sunil Thomas (ed.), Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases, Methods in Molecular Biology, Springer, New York, 2016. See also U.S. Pat. 5,762,939, the entire contents of each of which is incorporated by reference herein for all purposes. The SARS-CoV-2 spike proteins and polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) described herein may also be produced synthetically. The SARS-CoV-2 spike proteins and polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) described herein may be produced by using an egg-based manufacturing method. In some embodiments, the SARS-CoV-2 spike proteins and polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the vaccine composition are formulated in one or more carrier (e.g., a carrier described herein (see, e.g., § 5.7)). In some embodiments, the vaccine compositions are pharmaceutical compositions (e.g., described herein, e.g., see § 5.8). In some embodiments, the vaccine compositions comprise an adjuvant (e.g., described herein, e.g., see § 5.9). Attorney Docket No.62801.16WO01 5.5.2 Nucleic Acid-Based Vaccines In some embodiments, a nucleic acid molecule comprising a coding region encoding a SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.3) (or a fusion or conjugate thereof (see, e.g., § 5.4)) forms the basis for a vaccine composition (e.g., a prime vaccine composition, a booster composition, a vaccine prime and booster composition). Therefore, provided herein are, inter alia, vaccine compositions (e.g., prime vaccine compositions, booster compositions, vaccine prime and booster compositions) comprising a nucleic acid molecule comprising a coding region encoding at least one SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein (see, e.g., § 5.3) (or a fusion or conjugate thereof (see, e.g., § 5.4)). In some embodiments, the vaccine composition is a prime vaccine composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine booster composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine prime and booster composition of a prime-boost vaccine regimen. In some embodiments, the prime boost composition can be utilized as a prime and / or a booster (e.g., as described herein). In some embodiments, the vaccine composition forms a single dose vaccine that does not require a booster. In some embodiments, the vaccine composition comprises a plurality of nucleic acid molecules, each comprising a coding region encoding at least one SARS-CoV-2 spike protein or polypeptide (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) (e.g., described herein). In some embodiments, each of the nucleic acid molecules of the plurality are part of the same larger nucleic acid molecule. In some embodiments, each of the nucleic acid molecules of the plurality are separate (i.e., not connected) nucleic acid molecules. In some embodiments, at least two of the nucleic acid molecules of the plurality are part of the same larger nucleic acid molecule. In some embodiments, at least two of the nucleic acid molecules of the plurality are separate (i.e., not connected) nucleic acid molecules. In some embodiments, at least two of the nucleic acid molecules of the plurality are part of the same larger nucleic acid molecule; and at least one (e.g., at least 2, 3, 4, 5, etc.) of the nucleic acid molecules of the plurality is a separate (i.e., not connected) nucleic acid molecule. Attorney Docket No.62801.16WO01 In some embodiments, the plurality comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleic acid molecules. In some embodiments, the plurality comprises from about 2-100, 2-90, 2-80, 2-70, 2-60, 2-50, 2-40, 2-30, 2-20, 2-10, 2-5, 5-100, 5-90, 5-80, 5-70, 5-60, 5-50, 5-40, 5-30, 5-20, 5-10, 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 20-100, 20-90, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 30-100, 30-90, 30-80, 30-70, 30-60, 30-50, 30-40, 40-100, 40-90, 40-80, 40-70, 40-60, 40-50, 50-100, 50-90, 50-80, 50-70, 50-60, 60-100, 60-90, 60-80, 60-70, 70-100, 70-90, 70-80, 80-100, 80-90, or 90-100 nucleic acid molecules. In some embodiments, the plurality comprises at least 2 but no more than 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 nucleic acid molecules. In some embodiments, the amino acid sequence of each of the encoded SARS-CoV- 2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the plurality is different. In some embodiments, the amino acid sequence of at least one of the encoded SARS-CoV-2 spike proteins or polypeptides (e.g., immunogens (or immunogenic fragments and / or immunogenic variants thereof)) of the plurality is derived from a circulating strain of SARS-CoV-2. In some embodiments, the plurality comprises at least one encoded SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and / or immunogenic variant thereof)) described herein. In some embodiments, the plurality comprises at least one encoded SARS-CoV-2 spike protein or polypeptide (e.g., immunogen (or immunogenic fragment and...

Claims

Attorney Docket No.62801.16WO01 CLAIMS What is claimed is:

1. A nucleic acid molecule comprising at least one coding region encoding a SARS- CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), comprises at least one set of amino acid substitutions set forth in Table 2 or Table 4.

2. The nucleic acid molecule of claim 1, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) comprises a SARS-CoV-2 spike protein receptor binding domain (RBD).

3. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) consists of a SARS-CoV-2 spike protein receptor binding domain (RBD).

4. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) comprises a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2.

5. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) consists of a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2.

6. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a full-length SARS-CoV-2 spike protein.

7. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) consist of a full-length SARS-CoV-2 spike protein.Attorney Docket No.62801.16WO01 8. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2.

9. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.

10. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10-1100, 10-1200, or 10- 1300 amino acids.

11. The nucleic acid molecule of any one of the preceding claims, wherein other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 1-5).

12. The nucleic acid molecule of any one of the preceding claims, wherein other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1- 10 (e.g., any one of SEQ ID NOS: 1-5).

13. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2.Attorney Docket No.62801.16WO01 14. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 2.

15. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2.

16. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 1-5).

17. The nucleic acid molecule of any one of the preceding claims, wherein the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

18. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-2, that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.

19. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO: 1.Attorney Docket No.62801.16WO01 20. The nucleic acid molecule of any one of the preceding claims, wherein the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non- naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

21. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motif comprising a non- naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

22. The nucleic acid molecule of claim 20 or 21, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

23. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 3.

24. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-28.

25. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-16.

26. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%,Attorney Docket No.62801.16WO01 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-22.

27. The nucleic acid molecule of any one of the preceding claims, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 23-28.

28. The nucleic acid molecule of any one of claims 1-7, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4.

29. The nucleic acid molecule of claim 28, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.

30. The nucleic acid molecule of any one of claims 28-29, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10-1100, 10-1200, or 10- 1300 amino acids.

31. The nucleic acid molecule of any one of claims 28-30, wherein other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10).

32. The nucleic acid molecule of any one of claims 28-31, wherein other than the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of theAttorney Docket No.62801.16WO01 encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10).

33. The nucleic acid molecule of any one of claims 28-32, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4.

34. The nucleic acid molecule of any one of claims 28-33, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 4.

35. The nucleic acid molecule of any one of claims 28-34, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 4.

36. The nucleic acid molecule of any one of claims 28-35, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10 (e.g., any one of SEQ ID NOS: 6-10).

37. The nucleic acid molecule of any one of claims 28-36, wherein the encoded SARS- CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

38. The nucleic acid molecule of any one of claims 28-37, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-7, that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spikeAttorney Docket No.62801.16WO01 protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.

39. The nucleic acid molecule of any one of claims 28-38, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO:

1.

40. The nucleic acid molecule of any one of claims 28-39, wherein the encoded SARS- CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

41. The nucleic acid molecule of any one of claims 28-40, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motif comprising a non- naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

42. The nucleic acid molecule of claim 40 or 41, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

43. The nucleic acid molecule of any one of claims 28-42, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 5.

44. The nucleic acid molecule of any one of claims 28-43, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76.

45. The nucleic acid molecule of any one of claims 28-44, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%,Attorney Docket No.62801.16WO01 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44.

46. The nucleic acid molecule of any one of claims 28-45, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60.

47. The nucleic acid molecule of claims 28-46, wherein the amino acid sequence of encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61- 76.

48. The nucleic acid molecule of any one of claims 1-7, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4.

49. The nucleic acid molecule of claim 48, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.

50. The nucleic acid molecule of any one of claims 48-49, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10-1100, 10-1200, or 10- 1300 amino acids.

51. The nucleic acid molecule of any one of claims 48-50, wherein other than the at least one set of amino acid substitutions set forth in Table 2 and the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spikeAttorney Docket No.62801.16WO01 protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10.

52. The nucleic acid molecule of any one of claims 48-51, wherein other than the at least one set of amino acid substitutions set forth in Table 2 and the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

53. The nucleic acid molecule of any one of claims 48-52, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2.

54. The nucleic acid molecule of any one of claims 48-53, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 2.

55. The nucleic acid molecule of any one of claims 48-54, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2.

56. The nucleic acid molecule of any one of claims 48-55, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5.Attorney Docket No.62801.16WO01 57. The nucleic acid molecule of any one of claims 48-56, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4.

58. The nucleic acid molecule of any one of claims 48-57, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 or more sets of amino acid substitutions set forth in Table 4.

59. The nucleic acid molecule of any one of claims 48-58, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 4.

60. The nucleic acid molecule of any one of claims 48-59, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10.

61. The nucleic acid molecule of any one of claims 48-60, wherein the encoded SARS- CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

62. The nucleic acid molecule of any one of claims 48-61, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, or SEQ ID NO: 7, that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.

63. The nucleic acid molecule of any one of claims 48-62, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises aAttorney Docket No.62801.16WO01 proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO:

1.

64. The nucleic acid molecule of any one of claims 48-63, the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

65. The nucleic acid molecule of any one of any one of claims 48-64, wherein the amino acid sequence of the encoded SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

66. The nucleic acid molecule of claim 64 or 65, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

67. The nucleic acid molecule of any one of the preceding claims, wherein the encoded SARS-CoV-2 spike protein is an immunogen (or an immunogenic fragment and / or immunogenic variant thereof).

68. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule is an RNA molecule, a DNA molecule, or a DNA / RNA molecule.

69. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule is an RNA molecule.

70. The nucleic acid molecule of claim 68 or 69, wherein the RNA molecule is a translatable RNA molecule.

71. The nucleic acid molecule of any one of claims 68-70, wherein the RNA molecule is a messenger RNA (mRNA) molecule.

72. The nucleic acid molecule of any one of claims 68-70, wherein the RNA molecule is a circular RNA molecule.

73. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule comprises at least one modified nucleotide.

74. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule comprises N1-methyl-pseudouridine, cytosine, adenine, and guanine.

75. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule comprises a heterologous 5’-untranslated region (UTR), 3’-UTR, or both a 5’- UTR and 3’-UTR.Attorney Docket No.62801.16WO01 76. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule comprises a poly(A) sequence.

77. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule comprises a 5’cap structure.

78. The nucleic acid molecule of any one of the preceding claims, wherein the nucleotide sequence of the nucleic acid molecule is codon optimized.

79. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule further encodes a heterologous protein.

80. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule encodes a signal peptide.

81. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule encodes a homologous or heterologous signal peptide.

82. The nucleic acid molecule of any one of the preceding claims, wherein the nucleic acid molecule does not encode a signal peptide.

83. A vector comprising the nucleic acid molecule of any one of the preceding claims.

84. The vector of claim 83, wherein the vector is a non-viral vector (e.g., a plasmid) or a viral vector.

85. A conjugate comprising the nucleic acid molecule of any one of claims 1-82 operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous moiety (e.g., a heterologous protein).

86. A composition comprising at least one of the nucleic acid molecules set forth in any one of claims 1-82, the vector of any one of claims 83-84, or the conjugate of claim 85.

87. The composition of claim 86, comprising a plurality of nucleic acid molecules set forth in any one of claims 1-82, wherein the amino acid sequence of each of the SARS-CoV- 2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) encoded by each nucleic acid molecule of the plurality is different.

88. The composition of claim 87, wherein the plurality comprises at least two nucleic acid molecules set forth in any one of claims 1-82, wherein the amino acid sequence of each of the SARS-CoV-2 spike proteins (e.g., SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) encoded by of each of the at least 2 nucleic acid molecules comprises a different set of amino acid substitutions set forth in Table 2 or Table 4 or a different combination of sets of amino acid substitutions set forth in Table 2 or Table 4.Attorney Docket No.62801.16WO01 89. A composition comprising (a) at least one nucleic acid molecule set forth in any one of claims 8-27; (b) at least one nucleic acid molecule set forth in any one of claims 28-47; and / or (c) at least one nucleic acid molecule set forth in any one of claims 48-66.

90. The composition of any one of claims 86-89, wherein the nucleic acid molecule(s) are comprised in one or more vectors.

91. The composition of any one of claims 86-90, wherein the nucleic acid molecule(s) or the one or more vectors are formulated in one or more carrier.

92. The composition of any one of claims 86-91, further comprising a nucleic acid molecule encoding a SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4.

93. The composition of any one of claims 86-92, wherein the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient or a vaccine composition.

94. The composition of any one of claims 86-93, further comprising an adjuvant.

95. The composition of any one of claims 91-94, wherein the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome.

96. The composition of any one of claims 91-95, wherein the carrier is an LNP.

97. The composition of claim 96, wherein the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid.

98. The composition of claim 96 or 97, wherein the LNP has a mean particle size of between 80 nm and 160 nm.

99. A SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)), wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), comprises at least one set of amino acid substitutions set forth in Table 2 or Table 4.

100. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of claim 99, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a SARS-CoV-2 spike protein receptor binding domain (RBD).Attorney Docket No.62801.16WO01 101. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of claim 99 or 100, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) consists of a SARS-CoV-2 spike protein receptor binding domain (RBD).

102. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 101, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2.

103. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 102, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) consists of a fragment of a full-length SARS-CoV-2 spike protein that retains the ability to bind ACE2.

104. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 103, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a full-length SARS-CoV-2 spike protein.

105. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 104, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) consists of a full-length SARS-CoV-2 spike protein.

106. The SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 105, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2.

107. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 106, wherein theAttorney Docket No.62801.16WO01 amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.

108. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 106 or 107, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10- 90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10- 1100, 10-1200, or 10-1300 amino acids.

109. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 108, wherein other than the at least one set of amino acid substitutions, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-5.

110. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 109, wherein other than the at least one set of amino acid substitutions set forth in Table 2, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5.

111. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 110, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2.Attorney Docket No.62801.16WO01 112. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 111, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 2.

113. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 112, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%) amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2.

114. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 113, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5.

115. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 114, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

116. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 115, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 2 that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.Attorney Docket No.62801.16WO01 117. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 116, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO:

1.

118. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 117, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

119. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 118, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

120. The nucleic acid molecule of claim 118 or 119, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

121. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 120, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 3.

122. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 121, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,Attorney Docket No.62801.16WO01 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-28.

123. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 122, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 11-16.

124. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 123, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 17-22.

125. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 106- 124, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 23-28.

126. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 105, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 4.

127. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 126, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.Attorney Docket No.62801.16WO01 128. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 126 or 127, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises from about 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10- 90, 10-100, 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10- 1100, 10-1200, or 10-1300 amino acids.

129. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 128, wherein other than the at least one set of amino acid substitutions the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 6-10.

130. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 129, wherein other than the at least one set of amino acid substitutions the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10.

131. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 130, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4.

132. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 131, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 4.Attorney Docket No.62801.16WO01 133. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 132, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4.

134. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 133, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5.

135. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 134, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

136. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 135, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in in any one of SEQ ID NOS: 6-7 that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.

137. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 136, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to SEQ ID NO: 1.Attorney Docket No.62801.16WO01 138. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 137, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

139. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 138, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

140. The nucleic acid molecule of claim 138 or 139, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

141. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 140, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of a protein set forth in Table 5.

142. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 141, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-76.

143. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 142, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,Attorney Docket No.62801.16WO01 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 29-44.

144. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 143, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 45-60.

145. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 126- 144, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 61-76.

146. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 105, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one set of amino acid substitutions set forth in Table 2 and at least one set of amino acid substitutions set forth in Table 4.

147. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 146, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids.

148. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of claim 146 or 147, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 10-15, 10-20, 10-30, 10-40, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100,Attorney Docket No.62801.16WO01 10-200, 10-300, 10-400, 10-500, 10-600, 10-700, 10-800, 10-900, 10-1000, 10-1100, 10- 1200, or 10-1300 amino acids.

149. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 148, wherein other than the at least one set of amino acid substitutions, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a contiguous stretch of at least 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids set forth in any one of SEQ ID NOS: 1-10.

150. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 149, wherein other than the at least one set of amino acid substitutions set forth in Table 2 and the at least one set of amino acid substitutions set forth in Table 4, the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

151. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 150, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 2.

152. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 151, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, or 6 sets of amino acid substitutions set forth in Table 2.

153. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 152, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variantAttorney Docket No.62801.16WO01 thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not set forth in Table 2.

154. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 153, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 2 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-5.

155. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 154, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a plurality of sets of amino acid substitutions set forth in Table 4.

156. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 155, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 sets of amino acid substitutions set forth in Table 4.

157. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 156, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20% (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4.

158. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 157, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises 1 or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) but less than 20%Attorney Docket No.62801.16WO01 (e.g., less than 15%, less than 12%, less than 10%, less than 8%, less than 5%), amino acid variations (e.g., substitutions, additions, deletions, etc.) that are not listed in Table 4 relative to the amino acid sequence set forth in any one of SEQ ID NOS: 6-10.

159. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 158, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) is stabilized in a prefusion state.

160. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 159, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation relative to the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, or SEQ ID NO: 7, that stabilizes the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) in a prefusion state.

161. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 160, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a proline at amino acid position 986 and / or a proline at amino acid position 987, amino acid numbering relative to the amino acid positions set forth in SEQ ID NO:

1.

162. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 161, wherein SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises one or more non-naturally occurring glycosylation motif comprising a non-naturally occurring glycosylation site.

163. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 162, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises the addition of one or more non-naturally occurring glycosylation motifAttorney Docket No.62801.16WO01 comprising a non-naturally occurring glycosylation site relative to the amino acid sequence set forth in any one of SEQ ID NOS: 1-10.

164. The nucleic acid molecule of claim 162 or 163, wherein the non-naturally occurring glycosylation site is an N-glycosylation site.

165. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 164, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises an inactive furin cleavage site.

166. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 146- 165, wherein the amino acid sequence of the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises at least one amino acid variation in the furin cleavage site that inactivates the furin cleavage site.

167. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 166, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) further comprises a heterologous protein.

168. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 167, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a signal peptide.

169. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 168, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) comprises a homologous or heterologous signal peptide.

170. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 169, wherein the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike proteinAttorney Docket No.62801.16WO01 immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) does not comprise a signal peptide.

171. The SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-170, wherein the SARS-CoV-2 spike protein is an immunogen (or an immunogenic fragment and / or immunogenic variant thereof).

172. A fusion protein comprising the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous protein.

173. A conjugate comprising the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 operably connected (e.g., directly or indirectly (e.g., via a linker)) to a heterologous moiety.

174. A composition comprising at least one SARS-CoV-2 spike protein (e.g., at least one of the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)) set forth in any one of claims 99-174 or 186, the fusion protein of claim 172, the conjugate of claim 173, or the nucleic acid molecule of claim 185.

175. The composition of claim 174, wherein the composition comprises a plurality of SARS-CoV-2 spike proteins (e.g., a plurality of SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) set forth in any one of claims 99-171, wherein the amino acid sequence of each of the plurality of SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogens (or immunogenic fragments and / or immunogenic variants thereof)) comprises a different set of amino acid substitutions set forth in Table 2 or Table 4 or a different combination of sets of amino acid substitutions set forth in Table 2 or Table 4.

176. A composition comprising (a) at least one SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) set forth in any one of claims 106-125; (b) at least one SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) set forth in any one of claims 126-145; and / orAttorney Docket No.62801.16WO01 (c) at least one SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) set forth in any one of claims 146-165.

177. The composition of any one of claims 174-176, wherein the SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) are formulated in one or more carrier.

178. The composition of any one of claims 174-177, further comprising a SARS-CoV-2 spike proteins (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) that does not comprise a set of amino acid substitutions set forth in Table 2 or Table 4.

179. The composition of any one of claims 174-178, wherein the composition is a pharmaceutical composition comprising a pharmaceutically acceptable excipient.

180. The composition of any one of claims 174-179, further comprising an adjuvant.

181. The composition of any one of claims 174-180, wherein the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome.

182. The composition of any one of claims 174-181, wherein the carrier is an LNP.

183. The composition of claim 182, wherein the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid.

184. The composition of claim 182 or 183, wherein the LNP has a mean particle size of between 80 nm and 160 nm.

185. A nucleic acid molecule encoding the SARS-CoV-2 spike protein (e.g., the SARS- CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171.

186. A SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) encoded by the nucleic acid molecule of any one of claims 1-82.

187. A carrier comprising the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201.Attorney Docket No.62801.16WO01 188. The carrier of claim 187, wherein the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome.

189. The carrier of claim 188, wherein the carrier is an LNP.

190. The carrier of claim 188 or 189, wherein the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid.

191. The carrier of any one of claims 188-190, wherein the LNP has a mean particle size of between 80 nm and 160 nm.

192. A vaccine composition comprising the nucleic acid molecule of any one of claims 1- 82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, or the pharmaceutical composition of any one of claims 199-201.

193. The vaccine composition of claim 192, wherein the vaccine composition is a prime vaccine composition.

194. The vaccine composition of claim 192 or 193, wherein the vaccine composition is a boost vaccine composition.

195. The vaccine composition of any one of claims 192-194, wherein the vaccine composition is a prime vaccine composition and a boost vaccine composition.

196. The vaccine composition of any one of claims 192-195, wherein the vaccine composition can be utilized as a prime vaccine composition and / or a booster vaccine composition in a homologous or heterologous prime boost vaccine regimen.

197. A vaccine composition comprising a messenger ribonucleic acid (mRNA) encoding a SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) that comprises at least one amino acid substitution set forth in Table 2 or Table 4, formulated in a lipid nanoparticle, the vaccine composition having the following characteristics: (a) the LNPs comprise a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid, (b) the LNPs have a mean particle size of between 80 nm and 160 nm, and (c) the mRNA comprises: (i) a 5'-cap structure; (ii) a 5'- UTR; (iii) N1-methyl-pseudouridine, cytosine, adenine, and guanine; (iv) a 3'-UTR; and (v) a poly-A region.

198. The vaccine composition of any one of claims 192-197, wherein the vaccine composition further comprises an adjuvant.Attorney Docket No.62801.16WO01 199. A pharmaceutical composition comprising the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, or the vaccine composition of any one of claims 192-198, and a pharmaceutically acceptable excipient.

200. A pharmaceutical composition comprising a messenger ribonucleic acid (mRNA) encoding a SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein immunogen (or an immunogenic fragment and / or immunogenic variant thereof)) that comprises at least one amino acid substitution set forth in Table 2 or Table 4, formulated in a lipid nanoparticle, the pharmaceutical composition having the following characteristics: (a) the LNPs comprise a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid, (b) the LNPs have a mean particle size of between 80 nm and 160 nm, and (c) the mRNA comprises: (i) a 5'-cap structure; (ii) a 5'-UTR; (iii) N1-methyl-pseudouridine, cytosine, adenine, and guanine; (iv) a 3'-UTR; and (v) a poly-A region.

201. The pharmaceutical composition of any one of claims 199-200, wherein the pharmaceutical composition further comprises an adjuvant.

202. A host cell comprising the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201.

203. A kit comprising the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the cell of claim 202, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201.Attorney Docket No.62801.16WO01 204. The kit of claim 203, comprising instructions for use of the nucleic acid molecule, vector, protein (or immunogenic fragment or immunogenic variant thereof), conjugate, fusion protein, carrier, composition, vaccine composition, or pharmaceutical composition.

205. A method of delivering a nucleic acid molecule, vector, protein (or immunogenic fragment or immunogenic variant thereof), conjugate, fusion protein, host cell, carrier, composition, vaccine composition, or pharmaceutical composition to a subject in need thereof, the method comprising administering to the subject the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99- 171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201, to thereby deliver the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject.

206. A method of inducing or enhancing an immune response in a subject in need thereof, the method comprising administering to the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the vaccine composition of any one of claims 192- 198, or the pharmaceutical composition of any one of claims 199-201, to thereby induce or enhance an immune response the subject.

207. A method of preventing, ameliorating, or treating a SARS-CoV-2 infection in a subject in need thereof, the method comprising administering to the subject the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the vaccine compositionAttorney Docket No.62801.16WO01 of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199- 201, to thereby prevent, ameliorate, or treat the SARS-CoV-2 infection the subject.

208. A method of vaccinating a subject against SARS-CoV-2, the method comprising administering to the subject the nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187-191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201, to thereby vaccinate the subject against SARS-CoV-2.

209. A method of vaccinating a subject against SARS-CoV-2, the method comprising administering to the subject (a) an mRNA molecule (e.g., an mRNA molecule described herein) encoding the SARS-CoV-2 spike protein (e.g., a SARS-CoV-2 spike protein or polypeptide immunogen (or immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186 (or a conjugate or fusion protein thereof), (b) a vector comprising the mRNA molecule, (c) a carrier comprising the mRNA molecule or the vector, (d) a vaccine composition comprising the mRNA molecule, the vector, or the carrier, or (e) a pharmaceutical composition comprising the mRNA molecule, the vector, the carrier, or the vaccine composition, to thereby vaccinate the subject against SARS-CoV-2, to thereby vaccinate the subject against SARS-CoV-2.

210. A method of vaccinating a subject against SARS-CoV-2, the method comprising administering to the subject the vaccine composition of any one of claims 192-188 or the pharmaceutical composition of any one of claims 199-201, to thereby vaccinate the subject against SARS-CoV-2.

211. The method of any one of claims 205-210, wherein the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered to the subject at least twice.

212. The method of any one of claims 205-211, wherein the subject is a human.

213. The method of any one of claims 205-212, wherein the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusionAttorney Docket No.62801.16WO01 protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a prime and / or a boost in a homologous or heterologous prime-boost regimen.

214. The method of any one of claims 205-213, wherein the nucleic acid molecule, the vector, the SARS-CoV-2 spike protein (e.g., the SARS-CoV-2 spike protein immunogen (or immunogenic fragment and / or immunogenic variant thereof)), the conjugate, the fusion protein, the carrier, the composition, the vaccine composition, or the pharmaceutical composition is administered as a boost in a heterologous prime-boost regimen.

215. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use in the manufacture of a medicament for the inducement and / or enhancement of an immune response in a subject in need thereof.

216. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use in the manufacture of a medicament for the prevention, amelioration, and / or treatment of a SARS-CoV-2 infection in a subject in need thereof.

217. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use in the manufacture of a medicament for the vaccination a subject against SARS-CoV-2.Attorney Docket No.62801.16WO01 218. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use a method of inducing or enhancing an immune response in a subject in need thereof, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof.

219. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use in a method of preventing, ameliorating, and / or treating a SARS-CoV-2 infection in a subject in need thereof, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof.

220. The nucleic acid molecule of any one of claims 1-82 or 185, the protein (e.g., the SARS-CoV-2 spike protein immunogen (or the immunogenic fragment and / or immunogenic variant thereof)) of any one of claims 99-171 or 186, the vector of any one of claims 83-84, the conjugate of claim 85 or 173, the fusion protein of claim 172, the host cell of claim 202, the composition of any one of claims 86-98 or 174-184, the carrier of any one of claims 187- 191, the vaccine composition of any one of claims 192-198, or the pharmaceutical composition of any one of claims 199-201 for use in a method of vaccinating a subject against SARS-CoV-2, the method comprising administering the nucleic acid molecule, the protein, the vector, the conjugate, the fusion protein, the host cell, the carrier, the composition, the vaccine composition, or the pharmaceutical composition to the subject in need thereof.

Citation Information

Patent Citations

  • SARS-cov-2 neutralizing antibody or fragment thereof

    EP4219548A1

  • Binding molecule having neutralizing activity against coronavirus superfamily

    WO2022019711A1

  • SARS-CoV-2 NEUTRALIZING ANTIBODY OR FRAGMENT THEREOF

    WO2022065445A1

  • Immunogen selection

    WO2022235853A1